{"id":"CHEMBL107430","canonicalSmiles":"CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl","inchiKey":"PNAWUIKCVQSLFG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NRX195183","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AGN 195183","AGN-195183","IRX5183","NRX-195183","NRX195183","Nrx195183","VTP-195183","VTP-5183"],"crossReferences":{"drugbank":["DB05653"]},"count":1,"linkedTargets":{"rows":["ENSG00000131759"],"count":1},"linkedDiseases":{"rows":["EFO_0000224"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL108877","canonicalSmiles":"Oc1ccccc1Cl","inchiKey":"ISPYQTSUDJAMAB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"2-CHLOROPHENOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2-Chloro-Phenol","2-Chlorophenol"],"crossReferences":{"PubChem":["144208608","144210658","17389669","85272560"],"Wikipedia":["2-Chlorophenol"],"drugbank":["DB03110"],"chEBI":["47083"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1096562","canonicalSmiles":"COC(=O)CCC(=O)CN","inchiKey":"YUUAYBAIHCDHHD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METHYL AMINOLEVULINATE","yearOfFirstApproval":2004,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Metvix"],"synonyms":["Methyl aminolevulinate","Methyl-5-aminolevulinate"],"crossReferences":{"PubChem":["104171381"],"Wikipedia":["Methyl_aminolevulinate"],"drugbank":["DB00992"],"chEBI":["724125"]},"childChemblIds":["CHEMBL1201093"],"count":8,"approvedIndications":["EFO_0000616"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for neoplasm and has 7 investigational indications."}
{"id":"CHEMBL1098659","canonicalSmiles":"O","inchiKey":"XLYOFNOQVPJJNP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"WATER","yearOfFirstApproval":2011,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Pur-wash","Sterile water","Sterile water for injection"],"synonyms":["B1217","NSC-147337","Purified water","R-718","Sterile water for injection","Sterile water for irrigation","Water","Water for injection","Water purified","Water, purified"],"crossReferences":{"DailyMed":["purified%20water","sterile%20water%20for%20irrigation"],"Wikipedia":["Properties_of_water"],"drugbank":["DB09145"],"chEBI":["15377"]},"childChemblIds":["CHEMBL2105800","CHEMBL1232306","CHEMBL2106489"],"count":19,"approvedIndications":["EFO_0003885","Orphanet_365563"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for multiple sclerosis and primary short bowel syndrome and has 17 investigational indications."}
{"id":"CHEMBL1148","canonicalSmiles":"Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1","inchiKey":"NGBFQHCMQULJNZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TORSEMIDE","yearOfFirstApproval":1993,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Demadex","Torem 10","Torem 2.5","Torem 5","Torsemide"],"synonyms":["AC-4464","AC4464","BM-02.015","BM-02015","BM02.015","Torasemide","Torsemide"],"crossReferences":{"DailyMed":["torsemide"],"PubChem":["11112793","144204213","170465279","26719820","26748988","49665992","49666477"],"Wikipedia":["Torasemide"],"drugbank":["DB00214"],"chEBI":["9637"]},"count":6,"approvedIndications":["EFO_0003144","EFO_0000373","EFO_0000319","EFO_0000537"],"linkedTargets":{"rows":["ENSG00000074803"],"count":1},"linkedDiseases":{"rows":["EFO_0003144","EFO_0000373","EFO_0000319","EFO_0001360","EFO_0000668","EFO_0000537"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 4 approved and 2 investigational indications."}
{"id":"CHEMBL1162545","canonicalSmiles":"O=CC(=O)O","inchiKey":"HHLFWLYXYJOTON-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GLYOXYLATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2-Oxoacetate"],"crossReferences":{"Wikipedia":["Glyoxylic_acid"],"drugbank":["DB04343"],"chEBI":["16891"]},"childChemblIds":["CHEMBL3986754"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1162988","canonicalSmiles":"Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc([19F])cc3)c(O)c(=O)n2C)o1","inchiKey":"CZFFBEXEKNGXKS-JCEUWBQISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1162988","maximumClinicalTrialPhase":0,"parentId":"CHEMBL254316","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1163","canonicalSmiles":"COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C","inchiKey":"AXRYRYVKAWYZBR-GASGPIRDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ATAZANAVIR","yearOfFirstApproval":2003,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Reyataz"],"synonyms":["Atazanavir","BMS-232632","CGP-73547"],"crossReferences":{"DailyMed":["atazanavir%20sulfate"],"PubChem":["144206632","170465290"],"Wikipedia":["Atazanavir"],"drugbank":["DB01072"],"chEBI":["37924"]},"childChemblIds":["CHEMBL1200678"],"count":6,"approvedIndications":["EFO_0000763"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for viral disease and has 5 investigational indications."}
{"id":"CHEMBL1165","canonicalSmiles":"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O","inchiKey":"UWWDHYUMIORJTA-HSQYWUDLSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MOEXIPRIL","yearOfFirstApproval":1995,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Moexipril","RS-10085","Uniretic","Univasc"],"crossReferences":{"DailyMed":["moexipril%20hydrochloride"],"Wikipedia":["Moexipril"],"drugbank":["DB00691"],"chEBI":["6960"]},"childChemblIds":["CHEMBL1200534"],"count":2,"approvedIndications":["EFO_0000319"],"linkedTargets":{"rows":["ENSG00000159640"],"count":1},"linkedDiseases":{"rows":["EFO_0000319","EFO_1001486","EFO_0000537"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for cardiovascular disease and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1194287","canonicalSmiles":"CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1","inchiKey":"ICKFFNBDFNZJSX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHLOROPYRAMINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Chloropyramine","Halopyramine"],"crossReferences":{"PubChem":["11112580","174007197","50100492"],"drugbank":["DB08800"]},"childChemblIds":["CHEMBL550011"],"count":2,"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL119489","canonicalSmiles":"CN(C)c1cccc2c(S(N)(=O)=O)cccc12","inchiKey":"TYNBFJJKZPTRKS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL119489","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02866"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1200476","canonicalSmiles":"CCCCCCCCCCCCOS(=O)(=O)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O","inchiKey":"SKDGGFHGLZBNBC-YZPBMOCRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1200476","maximumClinicalTrialPhase":0,"parentId":"CHEMBL532","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1200554","canonicalSmiles":"CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O","inchiKey":"ZBVJFYPGLGEMIN-OYLNGHKZSA-N","drugType":"Protein","blackBoxWarning":false,"name":"TRIPTORELIN PAMOATE","yearOfFirstApproval":2000,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201334","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Trelstar","Triptodur kit"],"synonyms":["Triptorelin embonate","Triptorelin pamoate"],"crossReferences":{"DailyMed":["triptorelin%20pamoate"]},"count":5,"approvedIndications":["EFO_0000673","EFO_0001663"],"linkedTargets":{"rows":["ENSG00000109163"],"count":1},"linkedDiseases":{"rows":["EFO_0001065","MONDO_0000088","MONDO_0007254","EFO_0000673","MONDO_0008315","EFO_0001663"],"count":6},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for prostate adenocarcinoma and prostate carcinoma and has 3 investigational indications."}
{"id":"CHEMBL1200901","canonicalSmiles":"CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12.Cl","inchiKey":"WANGFTDWOFGECH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HALOFANTRINE HYDROCHLORIDE","yearOfFirstApproval":1992,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1107","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Halfan"],"synonyms":["Halofantrine hydrochloride","WR-171669"],"crossReferences":{"PubChem":["144204188","170465140","56463552"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1992."}
{"id":"CHEMBL1201050","canonicalSmiles":"Cc1cccn2c(=O)c(-c3nnn[n-]3)cnc12.[K+]","inchiKey":"NMMVKSMGBDRONO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PEMIROLAST POTASSIUM","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201198","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alamast"],"synonyms":["BMY-26517","Pemirolast potassium"],"crossReferences":{"PubChem":["144205991","170465431"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999."}
{"id":"CHEMBL1201082","canonicalSmiles":"CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1.Cl","inchiKey":"GIYXAJPCNFJEHY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"FLUOXETINE HYDROCHLORIDE","yearOfFirstApproval":1987,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL41","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Felicium","Fluoxetine","Fluoxetine hydrochloride","Olena","Oxactin","Prozac","Prozac 60","Prozac weekly","Prozep","Prozit","Ranflutin","Sarafem","Selfemra"],"synonyms":["Fluoxetine hydrochloride","LY-110140","LY110140"],"crossReferences":{"DailyMed":["fluoxetine%20hydrochloride"],"PubChem":["144207380","26747522","26747523","50106352","50106353","50106354","56422172","855820"]},"count":3,"approvedIndications":["EFO_0000289","EFO_0003761"],"linkedTargets":{"rows":["ENSG00000108576"],"count":1},"linkedDiseases":{"rows":["EFO_0000289","MONDO_0002050","EFO_0004262","MONDO_0002009","EFO_0003761"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for unipolar depression and bipolar disorder and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201087","canonicalSmiles":"C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21","inchiKey":"KORNTPPJEAJQIU-KJXAQDMKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CABERGOLINE","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cabaser","Cabergoline","Dostinex"],"synonyms":["Cabergoline","FCE 21336","FCE-21336"],"crossReferences":{"DailyMed":["cabergoline"],"PubChem":["144206142","170464667"],"Wikipedia":["Cabergoline"],"drugbank":["DB00248"],"chEBI":["3286"]},"count":13,"approvedIndications":["EFO_0002508"],"linkedTargets":{"rows":["ENSG00000149295"],"count":1},"linkedDiseases":{"rows":["Orphanet_64739","EFO_0002610","EFO_0000545","EFO_0001065","EFO_0002508","MONDO_0007254","EFO_1001110","EFO_0001073","MONDO_0002491","EFO_1001485","EFO_0000512","EFO_0004270","EFO_0000400","EFO_0008516"],"count":14},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for parkinson's disease and has 12 investigational indications."}
{"id":"CHEMBL1201255","canonicalSmiles":"CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1cn(Cc2ccccc2)cn1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1","inchiKey":"HHXHVIJIIXKSOE-QILQGKCVSA-N","drugType":"Protein","blackBoxWarning":false,"name":"HISTRELIN","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Supprelin"],"synonyms":["Histrelin","ORF 17070","ORF 17070RWJ 17070","ORF-17070","RWJ 17070","RWJ-17070"],"crossReferences":{"DailyMed":["histrelin%20acetate"],"Wikipedia":["Histrelin"],"chEBI":["5739"]},"childChemblIds":["CHEMBL1200509"],"count":3,"approvedIndications":["EFO_0000616"],"linkedTargets":{"rows":["ENSG00000109163"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0009029","EFO_0000673"],"count":3},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for neoplasm and has 2 investigational indications."}
{"id":"CHEMBL1201472","drugType":"Unknown","blackBoxWarning":false,"name":"ICODEXTRIN","yearOfFirstApproval":2002,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Extraneal"],"synonyms":["Icodextrin"],"crossReferences":{"DailyMed":["icodextrin"],"DrugCentral":["4105"],"Wikipedia":["Icodextrin"]},"count":2,"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 2 investigational indications."}
{"id":"CHEMBL1201488","drugType":"Protein","blackBoxWarning":false,"name":"SECRETIN SYNTHETIC HUMAN","yearOfFirstApproval":2004,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Chirhostim"],"synonyms":["Human secretin","Secretin Synthetic Human","Secretin human","Secretin synthetic human"],"crossReferences":{"DailyMed":["secretin%20synthetic%20human"]},"count":2,"linkedTargets":{"rows":["ENSG00000080293"],"count":1},"linkedDiseases":{"rows":["EFO_0003758","EFO_0004242"],"count":2},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 2 investigational indications."}
{"id":"CHEMBL1201492","drugType":"Small molecule","blackBoxWarning":false,"name":"SEVELAMER HYDROCHLORIDE","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Renagel"],"synonyms":["GT-16-026A","GT16-026A","Sevelamer hydrochloride"],"crossReferences":{"DailyMed":["sevelamer%20hydrochloride"],"Wikipedia":["Sevelamer"]},"count":5,"approvedIndications":["EFO_0003086","EFO_0003884"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for kidney disease and chronic kidney disease and has 3 investigational indications."}
{"id":"CHEMBL1201641","drugType":"Protein","blackBoxWarning":false,"name":"INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN","yearOfFirstApproval":1987,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Humulin u"],"synonyms":["Insulin zinc susp extended recombinant human"],"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 1987."}
{"id":"CHEMBL1204113","canonicalSmiles":"Br.NC(=O)N/N=C/c1ccc([N+](=O)[O-])o1","inchiKey":"MXAKZXXLBFTUNS-DCDCITSCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1204113","maximumClinicalTrialPhase":0,"parentId":"CHEMBL869","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1207374","canonicalSmiles":"O=c1[nH]cnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O","inchiKey":"GRSZFWQUAKGDAV-KQYNXXCUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1207374","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["26754274"],"drugbank":["DB04566"],"chEBI":["17202"]},"childChemblIds":["CHEMBL1627077"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1228","canonicalSmiles":"CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O","inchiKey":"HFHZKZSRXITVMK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXYPHENBUTAZONE","yearOfFirstApproval":1960,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"," United States"," Germany"," France"],"classes":["Dermatological toxicity"," Hematological toxicity"],"year":1984},"tradeNames":["Oxyphenbutazone","Tandearil"],"synonyms":["Oxyphenbutazone"],"crossReferences":{"PubChem":["144203965","170465310","26748182","56463172"],"Wikipedia":["Oxyphenbutazone"],"drugbank":["DB03585"],"chEBI":["76258"]},"childChemblIds":["CHEMBL3989676"],"linkedTargets":{"rows":["ENSG00000073756","ENSG00000095303"],"count":2},"linkedDiseases":{"rows":["HP_0002829","HP_0003326","EFO_0005752","EFO_0005755"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960. It was withdrawn in United Kingdom,  United States,  Germany and  France initially in 1984 due to Dermatological toxicity and  Hematological toxicity."}
{"id":"CHEMBL1229648","canonicalSmiles":"O=[N+]([O-])c1ccccc1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O","inchiKey":"KUWPCJHYPSUOFW-YBXAARCKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1229648","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["26731487"],"drugbank":["DB01920"],"chEBI":["90144"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1231840","canonicalSmiles":"[C-]#[O+]","inchiKey":"UGFAIRIUMAVXCW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CARBON MONOXIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Carbon monoxide"],"crossReferences":{"drugbank":["DB11588"],"chEBI":["17245"]},"childChemblIds":["CHEMBL2364719"],"count":4,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL1232142","canonicalSmiles":"Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1","inchiKey":"BYNQFCJOHGOKSS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SONECLOSAN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Soneclosan"],"crossReferences":{"drugbank":["DB04393"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1232510","canonicalSmiles":"CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(-c4cccc(N)c4)nn3)C(=O)O[C@]12C","inchiKey":"IXXFZUPTQVDPPK-ZAWHAJPISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SOLITHROMYCIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CEM 101","CEM-101","OP 1068","OP-1068","Solithromycin"],"crossReferences":{"drugbank":["DB09308"]},"count":5,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL1232889","canonicalSmiles":"O=C(O)c1c[nH]c(-c2ccccc2)n1","inchiKey":"XCAXKZJNJCKTQH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1232889","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07803"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1232960","canonicalSmiles":"O=C(O)c1conc1O","inchiKey":"JLPHBZYAQYOJND-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1232960","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02111"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1233598","canonicalSmiles":"N=C1N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]2N1","inchiKey":"WWVANQJRLPIHNS-ZKWXMUAHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"2-IMINOBIOTIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2-iminobiotin"],"crossReferences":{"drugbank":["DB03353"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1237135","canonicalSmiles":"CNCCCC12CCC(c3ccccc31)c1ccccc12.Cl","inchiKey":"NZDMFGKECODQRY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MAPROTILINE HYDROCHLORIDE","yearOfFirstApproval":1980,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL21731","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ludiomil","Maprotiline hydrochloride"],"synonyms":["Maprotiline hydrochloride"],"crossReferences":{"DailyMed":["maprotiline%20hydrochloride"],"PubChem":["144211309","14743087","152146163","26719700","26747580","26747581","50106647","50106648","56422491","855591"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1242","canonicalSmiles":"Nc1ccc(/N=N/c2ccccc2)c(N)n1","inchiKey":"QPFYXYFORQJZEC-FOCLMDBBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENAZOPYRIDINE","yearOfFirstApproval":1987,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["NSC-145895","Phenazopyridine"],"crossReferences":{"PubChem":["104171363"],"Wikipedia":["Phenazopyridine"],"drugbank":["DB01438"]},"childChemblIds":["CHEMBL1201022"],"count":3,"linkedTargets":{"rows":["ENSG00000196876","ENSG00000185313","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169432","ENSG00000168356","ENSG00000007314","ENSG00000136531","ENSG00000153253"],"count":10},"linkedDiseases":{"rows":["EFO_0003103","HP_0000016","EFO_0003901","EFO_0003843"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 3 investigational indications."}
{"id":"CHEMBL1256783","canonicalSmiles":"O.Oc1cc(O)c2c(c1)O[C@H](c1ccc(O)c(O)c1)[C@@H](O)C2","inchiKey":"OFUMQWOJBVNKLR-NQQJLSKUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"(+)-Catechin Hydrate","maximumClinicalTrialPhase":0,"parentId":"CHEMBL311498","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(+)-Catechin Hydrate"],"crossReferences":{"PubChem":["26732592"],"chEBI":["58994"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1278","canonicalSmiles":"CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1","inchiKey":"AMKVXSZCKVJAGH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NARATRIPTAN","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Amerge","Naratriptan"],"synonyms":["Amerge","Naratriptan"],"crossReferences":{"DailyMed":["naratriptan%20hydrochloride"],"Wikipedia":["Naratriptan"],"drugbank":["DB00952"],"chEBI":["7478"]},"childChemblIds":["CHEMBL1200601"],"count":2,"approvedIndications":["EFO_0003821"],"linkedTargets":{"rows":["ENSG00000135312","ENSG00000179546"],"count":2},"linkedDiseases":{"rows":["HP_0012075","EFO_0003821","EFO_0000677","HP_0002315"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for migraine disorder and has 1 investigational indication."}
{"id":"CHEMBL1297","canonicalSmiles":"CC(C(=O)O)c1cccc(Oc2ccccc2)c1","inchiKey":"RDJGLLICXDHJDY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"FENOPROFEN","yearOfFirstApproval":1976,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Progesic"],"synonyms":["53858","Fenoprofen","Nalfon"],"crossReferences":{"DailyMed":["fenoprofen%20calcium"],"Wikipedia":["Fenoprofen"],"drugbank":["DB00573"],"chEBI":["5004"]},"childChemblIds":["CHEMBL2068720","CHEMBL2103736","CHEMBL138241"],"count":1,"approvedIndications":["EFO_0005755"],"linkedTargets":{"rows":["ENSG00000073756","ENSG00000095303"],"count":2},"linkedDiseases":{"rows":["EFO_0005755"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976 and is indicated for rheumatic disease. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1329203","canonicalSmiles":"CCCCC(CC)COC(=O)c1ccccc1O","inchiKey":"FMRHJJZUHUTGKE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OCTISALATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Uvinul"],"synonyms":["Octisalate","Octyl salicylate"],"crossReferences":{"PubChem":["144205126","170465498","26754457","29215231"],"drugbank":["DB11062"],"chEBI":["88639"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1332546","canonicalSmiles":"CCC(C(=O)OCCOCCN(CC)CC)c1ccccc1","inchiKey":"DDVUMDPCZWBYRA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BUTAMIRATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Butamirate"],"crossReferences":{"PubChem":["26660763","29216339"],"drugbank":["DB13731"]},"childChemblIds":["CHEMBL2106133"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1337","canonicalSmiles":"O=C1CCCC(=O)C1C(=O)c1ccc(C(F)(F)F)cc1[N+](=O)[O-]","inchiKey":"OUBCNLGXQFSTLU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NITISINONE","yearOfFirstApproval":2002,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Nityr","Orfadin"],"synonyms":["Nitisinone","SC-0735"],"crossReferences":{"DailyMed":["nitisinone"],"PubChem":["174007248"],"Wikipedia":["Nitisinone"],"drugbank":["DB00348"],"chEBI":["50378"]},"count":2,"linkedTargets":{"rows":["ENSG00000158104"],"count":1},"linkedDiseases":{"rows":["MONDO_0043209","Orphanet_56","MONDO_0004741","HP_0000572"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 2 investigational indications."}
{"id":"CHEMBL1343453","canonicalSmiles":"Nc1ccc(C(=O)O)c(O)c1.Nc1ccc(C(=O)O)c(O)c1","inchiKey":"XRUKSARUAXTNEA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1343453","maximumClinicalTrialPhase":0,"parentId":"CHEMBL1169","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["855805"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1365576","canonicalSmiles":"Clc1ccc(Sc2cc(Cl)c(Cl)cc2Cl)cc1","inchiKey":"QUWSDLYBOVGOCW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TETRASUL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Tetrasul","V-101"],"crossReferences":{"PubChem":["144209590","144213301","29217921"],"drugbank":["DB12838"],"chEBI":["82162"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1380","canonicalSmiles":"Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1","inchiKey":"MCGSCOLBFJQGHM-SCZZXKLOSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ABACAVIR","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ziagen"],"synonyms":["Abacavir","Epzicom","Ziagen"],"crossReferences":{"DailyMed":["abacavir%20sulfate"],"PubChem":["26757979"],"Wikipedia":["Abacavir"],"drugbank":["DB01048"],"chEBI":["421707"]},"childChemblIds":["CHEMBL4303288","CHEMBL1200619","CHEMBL2106686"],"count":9,"approvedIndications":["EFO_0000763"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for viral disease and has 8 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1417019","canonicalSmiles":"Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21","inchiKey":"ZAHQPTJLOCWVPG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MITOXANTRONE HYDROCHLORIDE","yearOfFirstApproval":1987,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL58","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Mitoxantrone hydrochloride","Novantrone"],"synonyms":["CL 232,315","CL-232315","Mitoxantrone Dihcl","Mitoxantrone Dihydrochloride","Mitoxantrone dihydrochloride","Mitoxantrone hydrochloride","Mitozantrone","NSC-301739"],"crossReferences":{"PubChem":["144203748","170465183","26747571","26747572","26747573","50106605"],"chEBI":["50727"]},"count":34,"linkedTargets":{"rows":["ENSG00000131747"],"count":1},"linkedDiseases":{"rows":["MONDO_0000873","MONDO_0007254","EFO_1001469","EFO_0005952","EFO_1001052","MONDO_0003541","EFO_0000565","EFO_0004251","EFO_0000339","MONDO_0019460","EFO_0004289","EFO_0000330","EFO_0000673","EFO_0000182","EFO_1001830","EFO_0000196","MONDO_0020743","EFO_0008522","EFO_0000198","EFO_0000616","EFO_0000220","MONDO_0019457","MONDO_0008170","EFO_0000403","EFO_0000222","EFO_1000286","EFO_0003929","EFO_0000224","MONDO_0008315","EFO_0003843","EFO_0001663","EFO_0000211","EFO_0003885","MONDO_0001023","EFO_0000095","MONDO_0019472","EFO_0000574","EFO_0004256","MONDO_0018906","EFO_0001378"],"count":40},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 34 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1418176","canonicalSmiles":"C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O","inchiKey":"XWALNWXLMVGSFR-HLXURNFRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METHANDROSTENOLONE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"," United States"," Germany"," France"],"classes":["Misuse"],"year":1982},"tradeNames":["Dianabol"],"synonyms":["Metandienone","Methandienone","Methandrostenolone"],"crossReferences":{"PubChem":["144205200","170466069","29215353"],"Wikipedia":["Methandrostenolone"],"drugbank":["DB13586"]},"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in United Kingdom,  United States,  Germany and  France initially in 1982 due to Misuse."}
{"id":"CHEMBL1448","canonicalSmiles":"O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O","inchiKey":"RJMUSRYZPJIFPJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NICLOSAMIDE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ex A Lint","Lintex","Niclocide","Nicloside","Yomesan"],"synonyms":["BAY 2353","BAY-2353","NSC-178296","Niclosamide","WR 46234"],"crossReferences":{"PubChem":["104171199","11111533","11111534","124880876","144203760","144211066","170465184","174006693","26747596","26753613","50100291","50106712","50106713","56463356","85231153","90341111"],"Wikipedia":["Niclosamide"],"drugbank":["DB06803"]},"childChemblIds":["CHEMBL3794255"],"count":6,"approvedIndications":["EFO_1001342"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for helminthiasis and has 5 investigational indications."}
{"id":"CHEMBL1451277","canonicalSmiles":"CNCCc1ccccn1.CS(=O)(=O)O","inchiKey":"FUWLKZQYMWTFBA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1451277","maximumClinicalTrialPhase":0,"parentId":"CHEMBL24441","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["11113033","144204337","170465694"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1469","canonicalSmiles":"O=C(O)CCCc1ccccc1","inchiKey":"OBKXEAXTFZPCHS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENYLBUTANOIC ACID","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Phenylbutanoic acid","Phenylbutyrate"],"crossReferences":{"DailyMed":["sodium%20phenylbutyrate"],"PubChem":["67217","855904"],"drugbank":["DB06819"],"chEBI":["41500"]},"childChemblIds":["CHEMBL1746"],"count":6,"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 6 investigational indications."}
{"id":"CHEMBL1512507","canonicalSmiles":"C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl.O","inchiKey":"YCVUZJQETSDTPY-CYTOJJGESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1512507","maximumClinicalTrialPhase":0,"parentId":"CHEMBL80","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["56463307"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1516","canonicalSmiles":"CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1","inchiKey":"VTRAEEWXHOVJFV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OLMESARTAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Olmesartan","Olmesartan medoxomil impurity, olmesartan-","RNH-6270"],"crossReferences":{"PubChem":["174007156","26719844"],"Wikipedia":["Olmesartan"],"drugbank":["DB00275"],"chEBI":["48416"]},"count":4,"linkedTargets":{"rows":["ENSG00000144891"],"count":1},"linkedDiseases":{"rows":["EFO_0000275","EFO_0000712","EFO_1002032","EFO_0000407","EFO_0000537"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL1525826","canonicalSmiles":"COc1nccnc1NS(=O)(=O)c1ccc(N)cc1","inchiKey":"KXRZBTAEDBELFD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULFALENE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Kelfizina","Kelfizine w","Longum"],"synonyms":["AS-18908","NSC-110433","Sulfalene","Sulfamethopyrazine","Sulfametopyrazine"],"crossReferences":{"PubChem":["144205397","170465930","50086577"],"drugbank":["DB00664"],"chEBI":["32162"]},"count":2,"approvedIndications":["EFO_0000771"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for bacterial disease and has 1 investigational indication."}
{"id":"CHEMBL1596","canonicalSmiles":"CC1(C)S[C@@H]2[C@H](NC(=O)C(C(=O)Oc3ccc4c(c3)CCC4)c3ccccc3)C(=O)N2[C@H]1C(=O)O","inchiKey":"JIRBAUWICKGBFE-MNRDOXJOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CARBENICILLIN INDANYL","yearOfFirstApproval":1972,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Carbenicillin indanyl","Carindacillin"],"crossReferences":{"PubChem":["144206652","50126360"],"drugbank":["DB09319"],"chEBI":["52015"]},"childChemblIds":["CHEMBL1200991"],"count":2,"approvedIndications":["EFO_0000771"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for bacterial disease and has 1 investigational indication."}
{"id":"CHEMBL1604375","canonicalSmiles":"COP(=S)(OC)Oc1ccc(SC)c(C)c1","inchiKey":"PNVJTZOFSHSLTO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FENTHION","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Pro-spot","Spotton","Tiguvon"],"synonyms":["Fenthion"],"crossReferences":{"PubChem":["144204708","144208793","144210975","170466807","17389877","26753078","89854991"],"drugbank":["DB11412"],"chEBI":["34761"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1630842","canonicalSmiles":"CCN1c2ncc(CCOc3cc[n+]([O-])c4ccccc34)cc2C(=O)N(C)c2cccnc21","inchiKey":"BEMBRAMZGVDPMH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BILR 355","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bilr 355"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1646","canonicalSmiles":"CC1(C)C(/C=C/C=C/C=C/C=C2\\N(CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21.[Na+]","inchiKey":"MOFVSTNWEDAEEK-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"INDOCYANINE GREEN","yearOfFirstApproval":1959,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201304","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ic-green","Indocyanine green","Spy agent green kit"],"synonyms":["Indocyanine Green","Indocyanine green"],"crossReferences":{"DailyMed":["indocyanine%20green"],"PubChem":["144206227","57260468","57260469"],"Wikipedia":["Indocyanine_green"],"chEBI":["31696"]},"count":16,"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 16 investigational indications."}
{"id":"CHEMBL1652128","canonicalSmiles":"CC(C)(C)C(=O)OCOP(=O)(COC1(Cn2cnc3cnc(N)nc32)CC1)OCOC(=O)C(C)(C)C","inchiKey":"JLKJXDOWBVVABZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LB80380","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LB 80380","LB-80380","Lb80380"],"crossReferences":{"drugbank":["DB05020"]},"count":3,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL1654","canonicalSmiles":"O=P([O-])(O)C(O)(Cc1cccnc1)P(=O)(O)O.[Na+]","inchiKey":"DRFDPXKCEWYIAW-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"RISEDRONATE SODIUM","yearOfFirstApproval":1998,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL923","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Actonel","Atelvia","Risedronate sodium"],"synonyms":["NE-58095","NE-58095 ANHYDROUS","Risedronate sodium","Risedronic acid monosodium salt"],"crossReferences":{"DailyMed":["risedronate%20sodium"],"PubChem":["174006918"]},"count":6,"approvedIndications":["EFO_0003854","EFO_0003882"],"linkedTargets":{"rows":["ENSG00000160752"],"count":1},"linkedDiseases":{"rows":["EFO_0000565","EFO_0003957","EFO_0003854","MONDO_0007254","EFO_0000574","Orphanet_666","EFO_0003882","EFO_0004215"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for osteoporosis and postmenopausal osteoporosis and has 4 investigational indications."}
{"id":"CHEMBL1671","canonicalSmiles":"CC(C)NCC(O)COc1cccc2ccccc12.Cl","inchiKey":"ZMRUPTIKESYGQW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PROPRANOLOL HYDROCHLORIDE","yearOfFirstApproval":1967,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL27","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Angilol","Apsolol","Avlocardyl","Bedranol","Bedranol s.r.","Berkolol","Beta-prograne mr","Betadur cr","Cardinol","Dupromex","Half beta-prograne mr","Half propanix la","Half propatard la","Half-beprane cr","Half-betadur cr","Half-inderal la","Hemangeol","Inderal","Inderal la","Innopran","Innopran xl","Lederpronol","Lopranol la","Probeta la","Propanix la","Propanix-10","Propanix-160","Propanix-160 sr","Propanix-40","Propanix-80","Propatard la","Propranolol hydrochloride","Propranolol hydrochloride intensol","Rapranol sr","Sagittol","Slo-blok","Slo-pro","Sloprolol","Syprol","Tesnol"],"synonyms":["AY 64043","AY-64043","ICI 45520","ICI-45520","NSC-91523","Propranolol hydrochloride"],"crossReferences":{"DailyMed":["propranolol%20hydrochloride"],"PubChem":["144209084","144213222","17389750","26732618","26747603","26747604","26751803","46500341","50106744","50106745","50106746"],"chEBI":["8500"]},"count":14,"approvedIndications":["EFO_0003821","EFO_0000537"],"linkedTargets":{"rows":["ENSG00000169252","ENSG00000043591"],"count":2},"linkedDiseases":{"rows":["EFO_0002610","EFO_0004280","EFO_0003821","EFO_1001968","EFO_0001358","EFO_0001663","EFO_0000537","MONDO_0001187","EFO_0001422","EFO_0003860","EFO_0000389","EFO_0004142","EFO_0009545","MONDO_0043510","EFO_0001360","EFO_1000635"],"count":16},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for migraine disorder and hypertension and has 12 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1708","canonicalSmiles":"Cl.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1","inchiKey":"GELRVIPPMNMYGS-RVXRQPKJSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PAROXETINE HYDROCHLORIDE","yearOfFirstApproval":1992,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL490","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Paroxetine hydrochloride","Paxil","Paxil cr","Seroxat"],"synonyms":["Paroxetine HCl","Paroxetine hydrochloride","Paroxetine hydrochloride anhydrous"],"crossReferences":{"DailyMed":["paroxetine%20hydrochloride"],"PubChem":["26753519","85273719"]},"count":5,"approvedIndications":["EFO_0004262","MONDO_0002009","EFO_0003761"],"linkedTargets":{"rows":["ENSG00000108576"],"count":1},"linkedDiseases":{"rows":["EFO_0004262","MONDO_0002050","MONDO_0002009","EFO_0001645","EFO_0003761","EFO_0005230"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1738797","canonicalSmiles":"CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O","inchiKey":"KDGFLJKFZUIJMX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALECTINIB","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alecensa"],"synonyms":["AF-802","AF802","Alectinib","CH-5424802","CH5424802","RO-5424802","RO5424802"],"crossReferences":{"DailyMed":["alectinib%20hydrochloride"],"PubChem":["174006440"],"drugbank":["DB11363"]},"childChemblIds":["CHEMBL3707320"],"count":5,"approvedIndications":["EFO_0000616","EFO_0000311"],"linkedTargets":{"rows":["ENSG00000165731","ENSG00000171094"],"count":2},"linkedDiseases":{"rows":["EFO_0000616","EFO_0001421","EFO_0003060","EFO_0000519","EFO_0000311"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for neoplasm and cancer and has 3 investigational indications."}
{"id":"CHEMBL1742471","canonicalSmiles":"N=C(N)Nc1nc(CSCCN/C=N/S(=O)(=O)c2ccc(Br)cc2)cs1","inchiKey":"ZQHFZHPUZXNPMF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EBROTIDINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["Spain"],"classes":["Hepatotoxicity"],"year":1998},"tradeNames":[],"synonyms":["Ebrotidine"],"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in Spain  in 1998 due to Hepatotoxicity."}
{"id":"CHEMBL1742986","drugType":"Protein","blackBoxWarning":false,"name":"ATACICEPT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Atacicept","TACI-FC5","TACI-IG"],"count":6,"linkedTargets":{"rows":["ENSG00000161955","ENSG00000102524"],"count":2},"linkedDiseases":{"rows":["EFO_0003885","EFO_0000685","EFO_0007405","EFO_0005761","EFO_0002690","EFO_0004194"],"count":6},"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL1783256","canonicalSmiles":"CCCNC(=O)c1nnc2c(-c3cc(OC)ccc3OC)cccc2c1N","inchiKey":"NVWCZRPXYVDQEE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD6280","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD6280","Azd6280"],"crossReferences":{"drugbank":["DB12210"]},"count":1,"linkedTargets":{"rows":["ENSG00000011677","ENSG00000151834"],"count":2},"linkedDiseases":{"rows":["EFO_0005230"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1788331","canonicalSmiles":"Br.Br.Br.Br.Br.Br.Br.Br.O.O.c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1","inchiKey":"NTJWFYSLEIJDHO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1788331","maximumClinicalTrialPhase":0,"parentId":"CHEMBL18442","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1788386","canonicalSmiles":"CC(C)=CC1C(C(=O)OCN2C(=O)C3=C(CCCC3)C2=O)C1(C)C","inchiKey":"CXBMCYHAMVGWJQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TETRAMETHRIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Tetramethrin"],"crossReferences":{"PubChem":["50113148"],"drugbank":["DB13752"],"chEBI":["39397"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1835207","canonicalSmiles":"CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1","inchiKey":"JTMITOKKUMVWRT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"APRICOXIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Apricoxib","CS-706","R-109339","TG-01","TG01"],"crossReferences":{"drugbank":["DB12378"]},"count":3,"linkedTargets":{"rows":["ENSG00000073756"],"count":1},"linkedDiseases":{"rows":["EFO_0002618","MONDO_0007254","EFO_0003060"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL1865258","canonicalSmiles":"NS(=O)(=O)c1ccc(Cl)c(S(N)(=O)=O)c1","inchiKey":"NENBAISIHCWPKP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CLOFENAMIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Chloramidobenzol","Clofenamide","Monochlorphenamide"],"crossReferences":{"PubChem":["144205367","170466058","81066277"],"drugbank":["DB13663"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1899506","canonicalSmiles":"CN1CCCC(=C(c2cccs2)c2cccs2)C1","inchiKey":"JWIXXNLOKOAAQT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TIPEPIDINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AT 327","AT-327","CR-662","CRJ662","Tipepidine","Tipepidine hibenzate"],"crossReferences":{"PubChem":["144205981","50112677"],"drugbank":["DB13474"]},"count":3,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL1909286","canonicalSmiles":"CC(COc1ccccc1)NN","inchiKey":"QNEXFJFTGQBXBJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENOXYPROPAZINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"],"classes":["Hepatotoxicity"],"year":1966},"tradeNames":[],"synonyms":["Fenoxypropazine","Phenoxypropazine"],"crossReferences":{"PubChem":["144206870"],"Wikipedia":["Phenoxypropazine"],"drugbank":["DB09251"]},"childChemblIds":["CHEMBL4303424"],"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in United Kingdom  in 1966 due to Hepatotoxicity."}
{"id":"CHEMBL2052016","canonicalSmiles":"C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)[C@@]1(C)C3=CC=C(C(=O)OC)[C@H]1C(=O)OC","inchiKey":"YTZALCGQUPRCGW-MXVXOLGGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL2052016","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB00460"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL21","canonicalSmiles":"Nc1ccc(S(N)(=O)=O)cc1","inchiKey":"FDDDEECHVMSUSB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULFANILAMIDE","yearOfFirstApproval":1985,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Sulfanilamide"],"synonyms":["Sulfanilamide"],"crossReferences":{"PubChem":["11112170","144203902","144208529","144213653","170464653","17389527","47193670"],"Wikipedia":["Sulfanilamide"],"drugbank":["DB00259"],"chEBI":["45373"]},"count":1,"approvedIndications":["EFO_0000771"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985 and is indicated for bacterial disease."}
{"id":"CHEMBL2103739","canonicalSmiles":"CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O","inchiKey":"FWLKKPKZQYVAFR-LVEZLNDCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EMEDASTINE DIFUMARATE","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL594","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Emadine"],"synonyms":["AL-3432A","Emedastine difumarate"],"crossReferences":{"DailyMed":["emedastine%20difumarate"],"PubChem":["144206353","170465197"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997."}
{"id":"CHEMBL2104287","canonicalSmiles":"CN(C)CCN1C(=O)c2ccccc2N(C)c2ccccc21.Cl","inchiKey":"RJPZIQRLRMWPRF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIBENZEPIN HYDROCHLORIDE","maximumClinicalTrialPhase":4,"parentId":"CHEMBL1442422","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Noveril"],"synonyms":["Dibenzepin hydrochloride","HF 1927"],"crossReferences":{"PubChem":["144205337","170466001"]},"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL2105002","canonicalSmiles":"CC(CC(C#N)(c1ccccc1)C(C)C)N(C)C","inchiKey":"WFLSCFISQHLEED-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ISOAMINILE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dimyril"],"synonyms":["Isoaminile","Isoaminile citrate"],"crossReferences":{"PubChem":["170465846"]},"count":1,"approvedIndications":["HP_0012735"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for cough."}
{"id":"CHEMBL2105078","canonicalSmiles":"CCOC(=O)C1(c2ccccc2)CCN(CCOCC2CCCO2)CC1","inchiKey":"NNCOZXNZFLUYGG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FURETHIDINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Furethidine"],"crossReferences":{"drugbank":["DB01464"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2105696","canonicalSmiles":"COc1cccc(C(=O)Nc2ccc(OCCN3CCOCC3)c(-c3ccnn3C)c2)c1.Cl","inchiKey":"APWHJJLFCMBWQT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TEMANOGREL HYDROCHLORIDE","maximumClinicalTrialPhase":1,"parentId":"CHEMBL1084617","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["APD791","Temanogrel hydrochloride"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2105904","canonicalSmiles":"CCC1(CC)C(=O)[N-]C(=O)NC1=O.[Na+]","inchiKey":"RGHFKWPGWBFQLN-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"BARBITAL SODIUM","maximumClinicalTrialPhase":4,"parentId":"CHEMBL444","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Barbital sodium","Barbital, soluble","Barbitone sodium"],"crossReferences":{"PubChem":["144208060"]},"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL2106198","canonicalSmiles":"CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1","inchiKey":"PYMDEDHDQYLBRT-DRIHCAFSSA-N","drugType":"Protein","blackBoxWarning":false,"name":"BUSERELIN ACETATE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL2110824","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Suprefact"],"synonyms":["Buserelin acetate","Buserelin monoacetate","HOE 766","HOE-766"],"crossReferences":{"chEBI":["31324"]},"count":2,"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2106261","canonicalSmiles":"CCOC(=O)C(c1c(O)c2ccccc2oc1=O)c1c(O)c2ccccc2oc1=O","inchiKey":"JCLHQFUTFHUXNN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETHYL BISCOUMACETATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ethyl biscoumacetate","Ethyl biscumacetate","Ethyldicoumarol"],"crossReferences":{"PubChem":["170466152"],"drugbank":["DB08794"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2106548","canonicalSmiles":"COC(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccc(Cl)c(Cl)c1","inchiKey":"JKXQBIZCQJLVOS-GSNLGQFWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CLOMETOCILLIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Clometocillin"],"crossReferences":{"drugbank":["DB13686"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2106997","canonicalSmiles":"CCC(c1ccccc1)c1noc(CCN(CC)CC)n1","inchiKey":"OLTAWOVKGWWERU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PROXAZOLE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Aerbron"],"synonyms":["Proxazole"],"crossReferences":{"drugbank":["DB13819"]},"childChemblIds":["CHEMBL2104858"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2107065","canonicalSmiles":"CC[N+](C)(CC)CCSC1=Nc2ccccc2N=C(c2ccc(Sc3ccccc3)cc2)C1.[I-]","inchiKey":"YTSPICCNZMNDQT-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"TIBEZONIUM IODIDE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL2111016","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Tibezonium iodide"],"crossReferences":{"drugbank":["DB13702"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2107759","canonicalSmiles":"CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C","inchiKey":"GJQWFXNJAXOCBV-XVGNUGADSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MILATAXEL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MAC-321","Milataxel"],"count":4,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2107811","canonicalSmiles":"CO/N=C1\\CN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC12CNC2","inchiKey":"ZNPOCLHDJCAZAH-OEAKJJBVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZABOFLOXACIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Zabofloxacin"],"count":2,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2108210","drugType":"Small molecule","blackBoxWarning":false,"name":"LAVENDER OIL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FEMA NO. 2622","Lavandula angustifolia oil","Lavender oil"],"count":2,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2108494","drugType":"Protein","blackBoxWarning":false,"name":"INTERFERON","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Interferon"],"count":26,"approvedIndications":["EFO_1001888"],"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for eye infection and has 25 investigational indications."}
{"id":"CHEMBL2108508","drugType":"Protein","blackBoxWarning":true,"name":"INTERFERON ALFA-2A","yearOfFirstApproval":1986,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Roferon-a"],"synonyms":["INTERFERON ALFA-2A","Interferon alfa-2a","Interferon alfa-2a (genetical recombination)","RO 22-8181","RO-22-8181","RO-228181"],"count":13,"linkedTargets":{"rows":["ENSG00000159110","ENSG00000142166"],"count":2},"linkedDiseases":{"rows":["EFO_0000220","EFO_0003780","EFO_0000756","EFO_0000681","EFO_0000311","EFO_0004220","EFO_1000956","EFO_0000764","EFO_0000574","EFO_0000676","MONDO_0002367","EFO_0001378","EFO_0003047","EFO_0002617","EFO_1001156"],"count":15},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 13 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2108593","drugType":"Protein","blackBoxWarning":false,"name":"EPOETIN ZETA","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Retacrit"],"synonyms":["Epoetin zeta"],"crossReferences":{"DrugCentral":["5170"]},"linkedTargets":{"rows":["ENSG00000187266"],"count":1},"linkedDiseases":{"rows":["EFO_0000198"],"count":1},"description":"Protein drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL2108796","drugType":"Antibody","blackBoxWarning":false,"name":"MINRETUMOMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CC49","MAB-CC49","MOAB CC49","Minretumomab"],"count":7,"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL2109163","drugType":"Unknown","blackBoxWarning":false,"name":"HEPATITIS B VIRUS VACCINE INACTIVATED","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Engerix-b","H-b-vax","Heptavax-b"],"synonyms":["Hepatitis b virus vaccine inactivated"],"count":6,"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL2109327","drugType":"Antibody","blackBoxWarning":false,"name":"CSL-360","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CSL-360","Csl-360"],"count":1,"linkedTargets":{"rows":["ENSG00000185291"],"count":1},"linkedDiseases":{"rows":["EFO_0000222"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2109412","drugType":"Antibody","blackBoxWarning":false,"name":"L19SIP 131I","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["L19SIP","L19sip 131i"],"count":1,"linkedTargets":{"rows":["ENSG00000115414"],"count":1},"linkedDiseases":{"rows":["EFO_0003060","EFO_0000311"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2109429","drugType":"Antibody","blackBoxWarning":false,"name":"RG-7686","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["RG-7686"],"description":"Antibody drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL2109433","drugType":"Antibody","blackBoxWarning":false,"name":"OTILIMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GSK-3196165","GSK3196165","MOR-103","MOR103","Mor-103","Otilimab"],"count":3,"linkedTargets":{"rows":["ENSG00000164400"],"count":1},"linkedDiseases":{"rows":["EFO_0000694","EFO_0003885","EFO_0000685","EFO_0002506"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2109498","drugType":"Antibody","blackBoxWarning":false,"name":"IPH-2101","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1-7F9","IHP-2101","IPH-2101","IPH2101","Iph-2101"],"count":2,"linkedTargets":{"rows":["ENSG00000125498","ENSG00000243772"],"count":2},"linkedDiseases":{"rows":["EFO_0000222","EFO_0001378"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2109503","drugType":"Antibody","blackBoxWarning":false,"name":"LMB-9","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["B3 (DSFV) -PE (PSEUDOMONAS AERUGINOSA EXOTOXIN A)38","LMB-9","Lmb-9"],"count":8,"description":"Antibody drug with a maximum clinical trial phase of I (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL2109511","drugType":"Antibody","blackBoxWarning":false,"name":"ONTAMALIMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ontamalimab","PF-00547659","Pf-00547659","SHP-647","SHP647","Shp647"],"count":2,"linkedTargets":{"rows":["ENSG00000099866"],"count":1},"linkedDiseases":{"rows":["EFO_0000729","EFO_0000384"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2109635","drugType":"Antibody","blackBoxWarning":false,"name":"SAR-566658","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SAR-566658","SAR566658","Sar-566658","huDS6-DM4"],"count":2,"linkedTargets":{"rows":["ENSG00000185499"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0007254"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2110581","canonicalSmiles":"Cc1cn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)O[C@H]3C[C@H](n4cc(C)c(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@@H]3[C@@H](COP(=O)(O)O[C@@H]4[C@@H](COP(=O)(O)O[C@@H]5[C@@H](COP(=O)(O)O[C@@H]6[C@@H](COP(=O)(O)O[C@@H]7[C@@H](COP(=O)(O)O[C@@H]8[C@@H](COP(=O)(O)O[C@@H]9[C@@H](COP(=O)(O)O[C@@H]%10[C@@H](COP(=O)(O)O[C@@H]%11[C@@H](COP(=O)(O)O[C@@H]%12[C@@H](COP(=O)(O)O[C@@H]%13[C@@H](COP(=O)(O)O[C@@H]%14[C@@H](COP(=O)(O)O[C@@H]%15[C@@H](COP(=O)(O)O[C@@H]%16[C@@H](COP(=O)(O)O[C@@H]%17[C@@H](COP(=O)(O)O[C@@H]%18[C@@H](COP(=O)(O)O[C@@H]%19[C@@H](COP(=O)(O)O[C@@H]%20[C@@H](COP(=O)(O)O[C@@H]%21[C@@H](CO)O[C@@H](n%22cnc%23c(N)ncnc%23%22)[C@@H]%21O)O[C@@H](n%21ccc(N)nc%21=O)[C@@H]%20O)O[C@@H](n%20ccc(N)nc%20=O)[C@@H]%19O)O[C@@H](n%19ccc(=O)[nH]c%19=O)[C@@H]%18O)O[C@@H](n%18ccc(N)nc%18=O)[C@@H]%17O)O[C@@H](n%17cnc%18c(N)ncnc%18%17)[C@@H]%16O)O[C@@H](n%16ccc(N)nc%16=O)[C@@H]%15O)O[C@@H](n%15ccc(N)nc%15=O)[C@@H]%14O)O[C@@H](n%14cnc%15c(N)ncnc%15%14)[C@@H]%13O)O[C@@H](n%13cnc%14c(N)ncnc%14%13)[C@@H]%12O)O[C@@H](n%12cnc%13c(=O)[nH]c(N)nc%13%12)[C@@H]%11O)O[C@@H](n%11cnc%12c(=O)[nH]c(N)nc%12%11)[C@@H]%10O)O[C@@H](n%10ccc(N)nc%10=O)[C@@H]9O)O[C@@H](n9ccc(N)nc9=O)[C@@H]8O)O[C@@H](n8cnc9c(N)ncnc98)[C@@H]7O)O[C@@H](n7cnc8c(=O)[nH]c(N)nc87)[C@@H]6O)O[C@@H](n6ccc(N)nc6=O)[C@@H]5O)O[C@@H](n5cnc6c(N)ncnc65)[C@@H]4O)O[C@@H](n4ccc(N)nc4=O)[C@@H]3O)O2)c(=O)[nH]c1=O","inchiKey":"PRYZSLKPMFOUNL-MHIBGBBJSA-N","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"BEVASIRANIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bevasiranib"],"childChemblIds":["CHEMBL2103797"],"count":2,"description":"Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2142861","canonicalSmiles":"Cl.Cl.Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1","inchiKey":"AZUQEHCMDUSRLH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL2142861","maximumClinicalTrialPhase":0,"parentId":"CHEMBL101253","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["124893720","144207180"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2204263","canonicalSmiles":"O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3cncs3)CC2)C1","inchiKey":"CFKBNYUHQSQBSX-CYWCHRQTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"JNJ-41443532","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Jnj-41443532"],"crossReferences":{"drugbank":["DB12632"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2219425","canonicalSmiles":"CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21","inchiKey":"DDINXHAORAAYAD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ARIPIPRAZOLE LAUROXIL","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aristada","Aristada initio kit"],"synonyms":["ALKS 9072","ALKS-9070","ALKS-9072","Aripiprazole lauroxil","RDC-3317","RDC3317"],"crossReferences":{"DailyMed":["aripiprazole%20lauroxil"],"drugbank":["DB14185"]},"count":2,"approvedIndications":["EFO_0000692"],"linkedTargets":{"rows":["ENSG00000178394","ENSG00000149295","ENSG00000102468"],"count":3},"linkedDiseases":{"rows":["EFO_0000692","EFO_0005411"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for schizophrenia and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL225111","canonicalSmiles":"CC(C)=CCC[C@@H](C)[C@H]1CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CC[C@H](O)C(C)(C)[C@@H]1CC3","inchiKey":"CAHGCLMLTWQZNJ-BQNIITSRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LANOSTEROL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Lanostereol"],"crossReferences":{"PubChem":["26757817"],"Wikipedia":["Lanosterol"],"drugbank":["DB03696"],"chEBI":["16521"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL226117","canonicalSmiles":"CCCCCCCCCCCCCCCC(=O)NCC(=O)O","inchiKey":"KVTFEOAKFFQCCX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PALMITOYL GLYCINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["N-Ethanoyl-Hexadecanamide","N-Palmitoylglycine","Palmitoyl Glycine"],"crossReferences":{"drugbank":["DB03440"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL233553","canonicalSmiles":"CNS(=O)(=O)c1ccc(-c2ccc(/C=C3\\SC(=N)NC3=O)o2)cc1","inchiKey":"FJJJERLTHDXEPT-JYRVWZFOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL233553","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07533"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL234569","canonicalSmiles":"CCc1ccc(/C=C2\\SC(N[C@@H](c3ccc(F)cc3)c3nnn[nH]3)=NC2=O)o1","inchiKey":"BKZOQCGDCHOGOQ-MZLJFPOFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL234569","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08710"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL23552","canonicalSmiles":"O=P(O)(O)O[C@H]1[C@@H](O)[C@@H](OP(=O)(O)O)[C@H](O)[C@@H](OP(=O)(O)O)[C@@H]1OP(=O)(O)O","inchiKey":"CIPFCGZLFXVXBG-CNWJWELYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"Ionositol 1,3,4,5-Tetraphosphate","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ionositol 1,3,4,5-Tetraphosphate"],"crossReferences":{"drugbank":["DB01863"],"chEBI":["16783"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2365680","canonicalSmiles":"CCC(=O)N(c1ccccc1)C1CCN(CCc2cccs2)CC1C","inchiKey":"SRARDYUHGVMEQI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL2365680","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01439"],"chEBI":["53763"]},"childChemblIds":["CHEMBL2362021"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL236708","canonicalSmiles":"Nc1nc(O)c2ncn(CCCCC(F)(F)P(=O)(O)O)c2n1","inchiKey":"JANQQPWTLXUSCD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL236708","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04260"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL242737","canonicalSmiles":"C[C@H]1CC[C@@H](NCc2ccc3c(c2)Cc2c(-c4ccc(C(=O)O)cc4)n[nH]c2-3)CC1","inchiKey":"MEDLHZCDTXWLOC-GSXCWMCISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL242737","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07320"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL257619","canonicalSmiles":"CO[C@H](C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1","inchiKey":"CFCUWKMKBJTWLW-BKHRDMLASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL257619","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06810"],"chEBI":["31856"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL259551","canonicalSmiles":"Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12","inchiKey":"XVECMUKVOMUNLE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FR-180204","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FR-180204"],"crossReferences":{"PubChem":["174006438"],"drugbank":["DB07794"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL267431","canonicalSmiles":"COC[C@]1(OC)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(/C=N/O)cc3)C[C@@]21C","inchiKey":"GJMNAFGEUJBOCE-MEQIQULJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ASOPRISNIL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Asoprisnil","BAY86-5294","J-867","J867"],"crossReferences":{"Wikipedia":["Asoprisnil"],"drugbank":["DB06680"]},"count":6,"linkedTargets":{"rows":["ENSG00000082175"],"count":1},"linkedDiseases":{"rows":["EFO_0000731","EFO_0001065","HP_0000132","MONDO_0001572","HP_0100608","EFO_0003922"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL270190","canonicalSmiles":"C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1","inchiKey":"UPNUIXSCZBYVBB-JVFUWBCBSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ALVIMOPAN","yearOfFirstApproval":2008,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Entereg"],"synonyms":["ADL 8-2698","ADL-8-2698","Alvimopan","Alvimopan dihydrate","LY-246736","LY-246736 DIHYDRATE","LY246736"],"crossReferences":{"DailyMed":["alvimopan"],"Wikipedia":["Alvimopan"],"drugbank":["DB06274"]},"count":5,"approvedIndications":["HP_0002019"],"linkedTargets":{"rows":["ENSG00000112038"],"count":1},"linkedDiseases":{"rows":["MONDO_0004880","MONDO_0002158","MONDO_0008170","MONDO_0004567","MONDO_0002087","EFO_0003843","HP_0002019","MONDO_0001187"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for constipation and has 4 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL28318","canonicalSmiles":"Cc1c(C(C)C)c(=O)n(-c2ccccc2)n1C","inchiKey":"PXWLVJLKJGVOKE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PROPYPHENAZONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Isopropylantipyrine","Propyphenazone"],"crossReferences":{"PubChem":["144205786","170465821","26758034"],"Wikipedia":["Propyphenazone"],"drugbank":["DB13524"],"chEBI":["135538"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL293498","canonicalSmiles":"CC(C)=CCN1Cc2cc(Cl)cc3[nH]c(=S)n(c23)C[C@@H]1C","inchiKey":"RCSLUNOLLUVOOG-NSHDSACASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"R-82913","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["R-82913"],"crossReferences":{"drugbank":["DB08598"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL293776","canonicalSmiles":"COc1c(O)cc2oc(-c3ccc(O)cc3)cc(=O)c2c1O","inchiKey":"IHFBPDAQLQOCBX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HISPIDULIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-122415","TCMDC-123942"],"crossReferences":{"PubChem":["26725244","416148","50112864"],"drugbank":["DB14008"],"chEBI":["75902"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL297362","canonicalSmiles":"Cc1cccc(C)c1NC1=NCCCS1","inchiKey":"BPICBUSOMSTKRF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"XYLAZINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Xylazine"],"crossReferences":{"PubChem":["104171265","11111970","11111971","124881828","144203854","170466147","26747186","26752277","3712514","90341260"],"Wikipedia":["Xylazine"],"drugbank":["DB11477"]},"childChemblIds":["CHEMBL1256022"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3039543","drugType":"Antibody","blackBoxWarning":false,"name":"ULOCUPLUMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-936564","MDX-1338","Ulocuplumab"],"count":7,"linkedTargets":{"rows":["ENSG00000121966"],"count":1},"linkedDiseases":{"rows":["EFO_0009441","EFO_0000616","EFO_0000565","EFO_0000095","EFO_0000222","EFO_0001378","MONDO_0018906"],"count":7},"description":"Antibody drug with a maximum clinical trial phase of I (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL304858","canonicalSmiles":"C=CCN(C)CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1","inchiKey":"CMYCCJYVZIMDFU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL304858","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["124893195","29217636"],"drugbank":["DB02016"]},"childChemblIds":["CHEMBL324162"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3084748","canonicalSmiles":"O=C(O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1.[Cl-]","inchiKey":"RVCSYOQWLPPAOA-QKYUOBHYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"TROSPIUM CHLORIDE","yearOfFirstApproval":2004,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1888176","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Flotros","Regurin","Regurin xl","Sanctura","Sanctura xr","Spasmo-lyt","Trospium chloride","Uraplex"],"synonyms":["IP-631","IP631","Trospium chloride"],"crossReferences":{"DailyMed":["trospium%20chloride"],"PubChem":["144205995","170464918"]},"count":3,"approvedIndications":["EFO_1000781"],"linkedTargets":{"rows":["ENSG00000133019","ENSG00000181072"],"count":2},"linkedDiseases":{"rows":["EFO_1000781","EFO_0000341","EFO_0000692"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for overactive bladder and has 2 investigational indications."}
{"id":"CHEMBL310555","canonicalSmiles":"Oc1cccc2cccnc12","inchiKey":"MCJGNVYPOGVAJF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXYQUINOLINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Oxyquinoline"],"crossReferences":{"PubChem":["144064","144206634","144210184","144213967","17389213","17389852","24724293","26752756","49826123","68737"],"Wikipedia":["8-Hydroxyquinoline"],"drugbank":["DB11145"],"chEBI":["48981"]},"childChemblIds":["CHEMBL1697698","CHEMBL3251402","CHEMBL451260","CHEMBL1366480","CHEMBL3186026"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL315838","canonicalSmiles":"COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1","inchiKey":"PJWPNDMDCLXCOM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ENCAINIDE","yearOfFirstApproval":1986,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"," United States"],"classes":["Cardiotoxicity"],"year":1991},"tradeNames":[],"synonyms":["Encainide"],"crossReferences":{"drugbank":["DB01228"],"chEBI":["4788"]},"childChemblIds":["CHEMBL2106155"],"count":1,"approvedIndications":["EFO_0004269"],"linkedTargets":{"rows":["ENSG00000185313","ENSG00000153253","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169432","ENSG00000168356","ENSG00000136531","ENSG00000007314","ENSG00000196876"],"count":10},"linkedDiseases":{"rows":["EFO_0004269"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986 and is indicated for cardiac arrhythmia. It was withdrawn in United Kingdom and  United States initially in 1991 due to Cardiotoxicity."}
{"id":"CHEMBL316257","canonicalSmiles":"CCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC","inchiKey":"CITHEXJVPOWHKC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"L-Alpha-Dimyristoylphosphatidylcholine","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["L-Alpha-Dimyristoylphosphatidylcholine"],"crossReferences":{"PubChem":["144206232","50125764"],"drugbank":["DB11283"],"chEBI":["241349"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3183453","canonicalSmiles":"CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c([O-])c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C.[Na+]","inchiKey":"WWPRGAYLRGSOSU-RNROJPEYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"NOVOBIOCIN SODIUM","yearOfFirstApproval":1964,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL36506","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"],"classes":["Dermatological toxicity"," Hematological toxicity"," Hepatotoxicity"],"year":2009},"tradeNames":["Albamycin","Spheromycin","Vulcamycin"],"synonyms":["Novobiocin sodium"],"crossReferences":{"PubChem":["144204298","170465360"],"chEBI":["31924"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1964. It was withdrawn in United States  in 2009 due to Dermatological toxicity,  Hematological toxicity and  Hepatotoxicity."}
{"id":"CHEMBL325434","canonicalSmiles":"COc1ccc(OC)c(CN(C)c2ccc3nc(N)nc(N)c3c2)c1","inchiKey":"YBJANOUTWRTBDK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL325434","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02427"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL328139","canonicalSmiles":"C[C@H](O)[C@@H](CCc1cccc(Cl)c1Cl)n1cnc(C(N)=O)c1","inchiKey":"HCJYSIGJDKNVRU-TVQRCGJNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL328139","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03370"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL329433","canonicalSmiles":"NC(=O)c1cn([C@@H](CO)CCc2ccccc2)cn1","inchiKey":"ZUYUIKKHHBEVHL-GFCCVEGCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL329433","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02096"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL331057","canonicalSmiles":"O=C(Nc1ccc(Oc2ccc(C(=O)O)c(C(=O)O)c2)c(NC(=O)c2cccc([N+](=O)[O-])c2)c1)c1cccc([N+](=O)[O-])c1","inchiKey":"VFYAZSTYKPFSFL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL331057","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03067"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3349523","canonicalSmiles":"CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(N)=O)NC1=O","inchiKey":"SWXOGPJRIDTIRL-DOUNNPEJSA-N","drugType":"Protein","blackBoxWarning":false,"name":"CHEMBL3349523","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04894"]},"description":"Protein drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3349607","canonicalSmiles":"NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O","inchiKey":"VMZMNAABQBOLAK-DBILLSOUSA-N","drugType":"Protein","blackBoxWarning":false,"name":"CHEMBL3349607","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06663"],"chEBI":["72312"]},"description":"Protein drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3426621","canonicalSmiles":"C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12","inchiKey":"QSKQVZWVLOIIEV-NSHDSACASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RIPASUDIL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ripasudil"],"crossReferences":{"drugbank":["DB13165"]},"childChemblIds":["CHEMBL4594454"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL3526882","canonicalSmiles":"C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@H]3[C@H](C[C@H]4O[C@@H](CC[C@@H]1O2)C[C@@H](C)C4=C)O[C@H](C[C@H](O)CN)[C@@H]3OC.CC(=O)O","inchiKey":"GKVVTRHQRKCPDT-WRNBYXCMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3526882","maximumClinicalTrialPhase":0,"parentId":"CHEMBL1683590","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3542336","canonicalSmiles":"CCOC(=O)N[C@@H]1CC[C@H]2[C@H](/C=[14CH]/c3ccc(-c4cccc(F)c4)cn3)[C@@H]3[C@@H](C)OC(=O)[C@@H]3C[C@@H]2C1","inchiKey":"ZBGXUVOIWDMMJE-IHDLMBCHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3542336","maximumClinicalTrialPhase":0,"parentId":"CHEMBL493982","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3544983","canonicalSmiles":"COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1","inchiKey":"HVXKQKFEHMGHSL-QKDCVEJESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TESEVATINIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["EXEL-7647","KD-019","KD-020","KD019","Tesevatinib","XL647","Xl-647"],"crossReferences":{"drugbank":["DB11973"]},"childChemblIds":["CHEMBL3544982"],"count":6,"linkedTargets":{"rows":["ENSG00000146648","ENSG00000196411","ENSG00000141736"],"count":3},"linkedDiseases":{"rows":["MONDO_0007254","EFO_1001496","MONDO_0024880","EFO_0003060","Orphanet_731","EFO_0000519","EFO_0000311"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL3545048","drugType":"Small molecule","blackBoxWarning":false,"name":"AMG-319","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMG319","Amg-319","J3.391.906I"],"count":4,"linkedTargets":{"rows":["ENSG00000171608"],"count":1},"linkedDiseases":{"rows":["EFO_0000095","EFO_0000403","EFO_1001469","EFO_0000181"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL3545069","drugType":"Unknown","blackBoxWarning":false,"name":"PELAREOREP","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Reolysin"],"synonyms":["PO BB0209","PO-BB-0209","PO-BB0209","Pelareorep"],"count":6,"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL3545111","drugType":"Small molecule","blackBoxWarning":false,"name":"HEMAY-022","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Hemay-022"],"count":1,"linkedTargets":{"rows":["ENSG00000141736"],"count":1},"linkedDiseases":{"rows":["MONDO_0007254"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3545140","drugType":"Small molecule","blackBoxWarning":false,"name":"QC-12","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Qc-12"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545148","drugType":"Small molecule","blackBoxWarning":false,"name":"PHE377","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Phe377"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545227","drugType":"Small molecule","blackBoxWarning":false,"name":"NGD-8243","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MK-2295","MK-2295-005","Ngd-8243"],"count":1,"linkedTargets":{"rows":["ENSG00000196689"],"count":1},"linkedDiseases":{"rows":["EFO_0003843"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3545351","canonicalSmiles":"Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O","inchiKey":"HQLHZNDJQSRKDT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AV-101","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Av-101","J578.071C"],"count":3,"linkedTargets":{"rows":["ENSG00000161509","ENSG00000273079","ENSG00000116032","ENSG00000183454","ENSG00000105464","ENSG00000176884","ENSG00000198785"],"count":7},"linkedDiseases":{"rows":["EFO_0005762","MONDO_0002050","MONDO_0002009"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL3622821","canonicalSmiles":"CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12","inchiKey":"WYQFJHHDOKWSHR-MNOVXSKESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"UPADACITINIB","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Rinvoq"],"synonyms":["ABT-494","Upadacitinib"],"crossReferences":{"DailyMed":["upadacitinib"],"drugbank":["DB15091"]},"childChemblIds":["CHEMBL3707269"],"count":10,"approvedIndications":["EFO_0000685","EFO_0000540"],"linkedTargets":{"rows":["ENSG00000096968","ENSG00000162434","ENSG00000105639","ENSG00000105397"],"count":4},"linkedDiseases":{"rows":["EFO_1001209","EFO_0000729","EFO_0000685","EFO_1000710","EFO_0002690","EFO_0003898","EFO_0003778","EFO_0000274","EFO_0000540","EFO_0000384","EFO_0002609"],"count":11},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for rheumatoid arthritis and immune system disease and has 8 investigational indications."}
{"id":"CHEMBL366460","canonicalSmiles":"O=c1c(-c2ccccc2)coc2ccccc12","inchiKey":"GOMNOOKGLZYEJT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ISOFLAVONE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Isoflavone","NSC-135405"],"crossReferences":{"drugbank":["DB12007"],"chEBI":["18220"]},"count":6,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL3707252","canonicalSmiles":"C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12.C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12.O=P(O)(O)OCC(O)CO","inchiKey":"YZDDKALBXAGVHK-VMJVVOMYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"QUININE GLYCEROPHOSPHATE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL170","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Quinine glycerophosphate"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3707313","canonicalSmiles":"CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1","inchiKey":"MFBCDACCJCDGBA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRIFAROTENE","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aklief"],"synonyms":["CD-5789","CD5789","Trifarotene"],"crossReferences":{"DailyMed":["trifarotene"],"drugbank":["DB12808"]},"count":2,"approvedIndications":["EFO_0003894"],"linkedTargets":{"rows":["ENSG00000172819"],"count":1},"linkedDiseases":{"rows":["EFO_0000574","EFO_0003894"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for acne and has 1 investigational indication."}
{"id":"CHEMBL371405","canonicalSmiles":"C[C@@]12OC(=O)[C@]1([C@@H](O)[C@@H]1C=CCCC1)NC(=O)[C@@H]2CCCl","inchiKey":"NGWSFRIPKNWYAO-SHTIJGAHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MARIZOMIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Marizomib","NPI-0052","Salinosporamide a"],"crossReferences":{"Wikipedia":["Salinosporamide_A"],"drugbank":["DB11762"],"chEBI":["48045"]},"count":6,"linkedTargets":{"rows":["ENSG00000136930","ENSG00000100804","ENSG00000100902","ENSG00000106588","ENSG00000277791","ENSG00000041357","ENSG00000222028","ENSG00000154611","ENSG00000240065","ENSG00000204264","ENSG00000126067","ENSG00000101182","ENSG00000100567","ENSG00000143106","ENSG00000129084","ENSG00000205220","ENSG00000008018","ENSG00000142507","ENSG00000159377"],"count":19},"linkedDiseases":{"rows":["EFO_0000574","EFO_0001378","EFO_1000028","MONDO_0016700","EFO_0000519","EFO_0000311"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL3833320","drugType":"Antibody","blackBoxWarning":false,"name":"EPTINEZUMAB","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Vyepti"],"synonyms":["ALD-403","ALD403","Eptinezumab","Eptinezumab-jjmr"],"crossReferences":{"DailyMed":["eptinezumab-jjmr"]},"count":1,"approvedIndications":["EFO_0003821"],"linkedTargets":{"rows":["ENSG00000110680","ENSG00000175868"],"count":2},"linkedDiseases":{"rows":["EFO_0003821"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for migraine disorder."}
{"id":"CHEMBL38885","canonicalSmiles":"C[C@@H](CC(=O)O)[C@H](N)C(=O)O","inchiKey":"FHJNAFIJPFGZRI-UCORVYFPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL38885","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01898"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3893776","canonicalSmiles":"CN(C)C[C@@H]1CCCC[C@H]1c1cccc(O)c1.Cl","inchiKey":"SLOIWIHZXQWWIY-SLHAJLBXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3893776","maximumClinicalTrialPhase":0,"parentId":"CHEMBL2103829","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3975522","canonicalSmiles":"CC(C)[C@H](N)C(=O)OCC[C@H](NC(=O)[C@@H]1SCCN1S(=O)(=O)c1ccc(-c2ccccc2)cc1)c1ccc(F)cc1","inchiKey":"UUIBKACUTXYSAK-YCVJPRETSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EBOPIPRANT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ebopiprant","OBE-022","OBE022","Obe022"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3989837","canonicalSmiles":"CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CSc3ccncc3)[C@H]2SC1.CC(=O)OCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)CSc3ccncc3)[C@H]2SC1.c1ccc(CNCCNCc2ccccc2)cc1","inchiKey":"JAHKOXGROZNHHG-RACYMRPCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEPHAPIRIN BENZATHINE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL1599","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cephapirin benzathine"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL402001","canonicalSmiles":"O=P(O)(O)OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O","inchiKey":"NBSCHQHZLSJFNQ-PQMKYFCFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MANNOSE-6-PHOSPHATE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Juvidex","Mannose 6-phosphate","Mannose-6-phosphate"],"crossReferences":{"drugbank":["DB02900"],"chEBI":["43896"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL404520","canonicalSmiles":"CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12","inchiKey":"CYDMQBQPVICBEU-XRNKAMNCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHLORTETRACYCLINE","yearOfFirstApproval":1950,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Chlortetracycline","E702"],"crossReferences":{"drugbank":["DB09093"],"chEBI":["27644"]},"childChemblIds":["CHEMBL2146100","CHEMBL2146063","CHEMBL2106006"],"count":4,"approvedIndications":["EFO_0000771","EFO_0000544","EFO_1001888"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 3 approved and 1 investigational indication."}
{"id":"CHEMBL406050","canonicalSmiles":"CCC(C)SSc1ncc[nH]1","inchiKey":"BPBPYQWMFCTCNG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PX-12","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Px-12"],"crossReferences":{"PubChem":["174006855"],"drugbank":["DB05448"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL406973","canonicalSmiles":"OC[C@@H]1NC[C@H](O)[C@H]1O","inchiKey":"OQEBIHBLFRADNM-YUPRTTJUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL406973","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03411"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL411","canonicalSmiles":"CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1","inchiKey":"RGLYKWWBQGJZGM-ISLYRVAYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIETHYLSTILBESTROL","yearOfFirstApproval":1973,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"]},"tradeNames":["Apstil","Diethylstilbestrol","Distilbene","Stilbestrol","Stilbetin","Stilboesterol","Tampovagan"],"synonyms":["Cyren a","Diethylstilbestrol","Estrobene","Estrogenine","Estromenin","Fonatol","NSC-3070","New-estranol 1","Palestrol","Stilbestroform","Stilbestrol","Stilboestrol","Synestrin","Synthestrin"],"crossReferences":{"PubChem":["11532921","144209605","144210844","17389919","26747240","26752777"],"Wikipedia":["Diethylstilbestrol"],"drugbank":["DB00255"],"chEBI":["41922"]},"count":2,"approvedIndications":["EFO_0000616"],"linkedTargets":{"rows":["ENSG00000091831"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0008315"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for neoplasm and has 1 investigational indication. It was withdrawn in United States."}
{"id":"CHEMBL4297216","canonicalSmiles":"Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O","inchiKey":"QAFZLTVOFJHYDF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FEDRATINIB HYDROCHLORIDE","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1287853","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Inrebic"],"synonyms":["Fedratinib hydrochloride","SAR302503A"],"crossReferences":{"DailyMed":["fedratinib%20hydrochloride"]},"count":1,"approvedIndications":["EFO_0002430"],"linkedTargets":{"rows":["ENSG00000096968","ENSG00000122025"],"count":2},"linkedDiseases":{"rows":["EFO_0002430"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for primary myelofibrosis."}
{"id":"CHEMBL4297267","canonicalSmiles":"CSCO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]12C)C3(C)C","inchiKey":"UBJAHGAUPNGZFF-XOVTVWCYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BMS-184476","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["7-methylthiomethylpaclitaxel","Bms-184476"],"crossReferences":{"drugbank":["DB12633"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297336","canonicalSmiles":"C[11C](=O)O","inchiKey":"QTBSBXVTEAMEQO-JVVVGQRLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACETIC ACID C-11","maximumClinicalTrialPhase":2,"parentId":"CHEMBL539","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["11c-acetate","Acetic acid c-11"],"crossReferences":{"drugbank":["DB15111"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297369","canonicalSmiles":"CC(=O)Nc1ccc(C(=O)NC(C)(C)C)cc1","inchiKey":"DJKNRCWSXSZACF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CP1-1189","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CPI-1189","Cp1-1189","Cpi-1189"],"crossReferences":{"drugbank":["DB12311"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297370","canonicalSmiles":"O=c1cc(NCCCN[C@@H]2CCOc3c(Br)cc(Br)cc32)[nH]c2ccsc12","inchiKey":"NNTYBKTXMKBRFA-CQSZACIVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CRS-3123","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CRS3123","Crs-3123","Crs3123","REP-3123","REP3123"],"crossReferences":{"drugbank":["DB12262"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297540","canonicalSmiles":"N#CCCCSC(=N)N","inchiKey":"PRDJGNVQBVXXEO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"4-ISOTHIOUREIDOBUTYRONITRILE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-isothioureidobutyronitrile","Kevetrin","NSC-525990","Thioureidobutyronitrile"],"crossReferences":{"drugbank":["DB13010"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297574","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"TEPRASIRAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["I5-NP","I5NP","QPI-1002","Qpi-1002","Teprasiran"],"count":1,"description":"Oligonucleotide drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4297595","canonicalSmiles":"N#CCCNc1nonc1-c1nc2ccccc2n1CC(=O)c1ccc(NC(=O)[C@@H](N)CCCCN)cc1","inchiKey":"NIPZLALJRAHABJ-IBGZPJMESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LISAVANBULIN","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BAL 101553","BAL-101553","BAL101553","Bal101553","Lisavanbulin","MICROTUBULE-TARGETED AGENT BAL101553","Microtubule-targeted agent bal101553"],"crossReferences":{"drugbank":["DB15224"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297606","canonicalSmiles":"COc1ccc(-c2cc(=O)c3c(OC)cc(OCC(=O)O)cc3o2)cc1OC","inchiKey":"BCPQOBQIVJZOFL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RECOFLAVONE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["DA 6034","DA-6034","Da-6034","Recoflavone"],"crossReferences":{"drugbank":["DB12058"]},"count":2,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297675","canonicalSmiles":"CC(=O)OC[C@H](COc1ccc(C(C)(C)c2ccc(OC[C@@H](CCl)OC(C)=O)cc2)cc1)OC(C)=O","inchiKey":"HGHVYYKTOXUQNT-CLJLJLNGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RALANITEN ACETATE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Epi-506","Ralaniten acetate"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297789","drugType":"Unknown","blackBoxWarning":false,"name":"MT-3724","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mt-3724"],"count":3,"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4298025","drugType":"Antibody","blackBoxWarning":false,"name":"ZENOCUTUZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MCLA-128","Mcla 128","Mcla-128","Zenocutuzumab"],"count":1,"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4298031","drugType":"Antibody","blackBoxWarning":false,"name":"GREMUBAMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Gremubamab","MEDI-3902","MEDI3902","Medi 3902","Medi3902"],"count":1,"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4298070","drugType":"Unknown","blackBoxWarning":false,"name":"PROGRAMMED CELL DEATH 1 LIGAND 1","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Pd-l1","Programmed cell death 1 ligand 1"],"count":5,"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL4298194","drugType":"Gene","blackBoxWarning":false,"name":"GIROCTOCOGENE FITELPARVOVEC","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Giroctocogene fitelparvovec","PF-07055480","SB-525"],"count":1,"description":"Gene drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4302089","canonicalSmiles":"OC1CN(CCCOCCc2ccc3sccc3c2)C1","inchiKey":"HQNACSFBDBYLJP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"T-817","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB05938"]},"childChemblIds":["CHEMBL4297438"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL431698","canonicalSmiles":"Oc1ccc(-c2cc3ccc(O)cc3s2)cc1","inchiKey":"MDGWZLQPNOETLH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RALOXIFENE CORE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08773"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL442565","canonicalSmiles":"CC1=CCC2CC1C2(C)C","inchiKey":"GRWFGVWFFZKLTI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALPHA-PINENE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[".alpha.-pinene","Alpha-pinene","FEMA NO. 2902","NSC-7727","PC-500","PC-500(TERPENE)"],"crossReferences":{"PubChem":["144207306","17389183"],"drugbank":["DB15573"],"chEBI":["36740"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL445332","canonicalSmiles":"COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C","inchiKey":"OBSYBRPAKCASQB-AGQYDFLVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SALVINORIN A","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Salvinorin a"],"crossReferences":{"PubChem":["26755778","29216411"],"Wikipedia":["Salvinorin_A"],"drugbank":["DB12327"],"chEBI":["67900"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL445647","canonicalSmiles":"CC(C)CC(=O)C(=O)O","inchiKey":"BKAJNAXTPSGJCU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"2-Oxoisohexanoate","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2-Oxoisohexanoate","alpha-Ketoisocaproate","alpha-Oxoisohexanoate"],"crossReferences":{"Wikipedia":["Alpha-Ketoisocaproic_acid"],"drugbank":["DB03229"],"chEBI":["48430"]},"childChemblIds":["CHEMBL2142054","CHEMBL2361069"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL446452","canonicalSmiles":"c1ccc2c(Cc3c[nH]c4ccccc34)c[nH]c2c1","inchiKey":"VFTRKSBEFQDZKX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ARUNDINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1,1-Bis(3'-Indolyl)Methane","3,3'-Diindolylmethane","3,3-Diindolylmethane","Arundine","Diindolylmethane"],"crossReferences":{"PubChem":["174007202","26749354","26753756","26753757","26753758","529850"],"Wikipedia":["3,3%27-Diindolylmethane"],"drugbank":["DB11875"],"chEBI":["50182"]},"count":3,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4594251","canonicalSmiles":"CS(=O)(=O)O.CS(=O)(=O)O.Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1","inchiKey":"QQDRLKRHJOAQDC-FBHGDYMESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NETARSUDIL DIMESYLATE","yearOfFirstApproval":2017,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL4594250","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Rhopressa"],"synonyms":["AR-13324","Netarsudil dimesylate","Netarsudil mesilate","Netarsudil mesylate"],"crossReferences":{"DailyMed":["netarsudil%20dimesylate","netarsudil%20mesylate"]},"count":2,"approvedIndications":["EFO_0004190","EFO_1001069"],"linkedTargets":{"rows":["ENSG00000134318","ENSG00000067900"],"count":2},"linkedDiseases":{"rows":["EFO_0004190","EFO_1001069"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for ocular hypertension and open-angle glaucoma."}
{"id":"CHEMBL46","canonicalSmiles":"Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O","inchiKey":"FELGMEQIXOGIFQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ONDANSETRON","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ondansetron","Zofran","Zofran odt","Zuplenz"],"synonyms":["A04AA01","Desmethylondansetron","EUR-1025","GR-38032","GR-38032F","Ondansetron","Zofran"],"crossReferences":{"DailyMed":["ondansetron","ondansetron%20hydrochloride"],"PubChem":["124893606","144206599","170464701"],"Wikipedia":["Ondansetron"],"drugbank":["DB00904"],"chEBI":["7773"]},"childChemblIds":["CHEMBL1487310","CHEMBL1201111","CHEMBL3186492"],"count":33,"approvedIndications":["EFO_0006911","HP_0002017","EFO_0004888","EFO_0006912","HP_0002018"],"linkedTargets":{"rows":["ENSG00000166736"],"count":1},"linkedDiseases":{"rows":["EFO_0003869","EFO_0002610","HP_0000989","EFO_1001219","EFO_0000555","MONDO_0007254","EFO_0003768","EFO_0005952","HP_0002018","EFO_0003829","EFO_0007191","MONDO_0001416","MONDO_0002046","HP_0005184","EFO_0000096","EFO_0003144","HP_0002017","EFO_0008546","HP_0002013","EFO_0004701","EFO_0004242","EFO_0000692","EFO_0005762","EFO_0000616","EFO_0002618","HP_0002094","EFO_0004799","EFO_0005774","EFO_0004210","EFO_0006911","HP_0012532","HP_0011110","EFO_0003843","MONDO_0008315","EFO_0006912","HP_0002315","HP_0000738","EFO_0000311","MONDO_0015917","EFO_1001463","EFO_0001061","Orphanet_79292","EFO_0000764","EFO_0004888","EFO_0005611","MONDO_0043510","EFO_0000691","EFO_0005251","EFO_0007386"],"count":49},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 5 approved and 28 investigational indications."}
{"id":"CHEMBL460962","canonicalSmiles":"C[C@@H]1CN(CC2(C(N)=O)CC2)CCN1S(=O)(=O)c1ccc([C@](C)(O)C(F)(F)F)cc1","inchiKey":"YJFULAYRAKPBCY-DYVFJYSZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL460962","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07624"]},"childChemblIds":["CHEMBL3357072"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL461006","canonicalSmiles":"CS(=O)(=O)O.Cc1cc(Cn2nnc3c(-c4ccco4)nc(N)nc32)ccc1N","inchiKey":"RTUYUZIQJWZNHT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL461006","maximumClinicalTrialPhase":0,"parentId":"CHEMBL447664","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL471036","canonicalSmiles":"c1ccc2cc(COC3CCNCC3)ccc2c1","inchiKey":"MJJDYOLPMGIWND-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LITOXETINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Litoxetine"],"crossReferences":{"Wikipedia":["Litoxetine"],"drugbank":["DB15038"]},"count":1,"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL471498","canonicalSmiles":"O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1","inchiKey":"WPGGHFDDFPHPOB-BBWFWOEESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MITIGLINIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mitiglinide"],"crossReferences":{"Wikipedia":["Mitiglinide"],"drugbank":["DB01252"]},"childChemblIds":["CHEMBL1603301"],"count":2,"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL485961","canonicalSmiles":"CCc1nc(N)nc(N)c1C#CCc1cc(OC)ccc1OC","inchiKey":"NNFDQABYXZBKRK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL485961","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08234"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL489095","canonicalSmiles":"C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1","inchiKey":"RZKDEGZIFSJVNA-IBGZPJMESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CAMICINAL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Camicinal","GSK-962040","GSK-962040B","GSK962040","GSK962040B","Gsk962040"],"crossReferences":{"drugbank":["DB12567"]},"childChemblIds":["CHEMBL489679"],"count":1,"linkedTargets":{"rows":["ENSG00000102539"],"count":1},"linkedDiseases":{"rows":["EFO_1000948"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL498623","canonicalSmiles":"O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)Nc1ccc([123I])cc1)C(=O)O)C(=O)O","inchiKey":"LFEGKCKGGNXWDV-NKNRFTOXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MIP-1095 I-123","maximumClinicalTrialPhase":1,"parentId":"CHEMBL456029","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["123-i-mip-1095","Mip-1095 i-123"],"crossReferences":{"drugbank":["DB12994"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL499","canonicalSmiles":"CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1","inchiKey":"BLJRIMJGRPQVNF-JTQLQIEISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TIMOLOL","yearOfFirstApproval":1978,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Betim","Betimol","Blocadren","Glau-opt","Glaucol","Nyogel","Timolol","Timoptic","Tiopex"],"synonyms":["Blocadren","Istalol","Timolol","Timolol hemihydrate","Timoptic","Timoptic-XE"],"crossReferences":{"DailyMed":["timolol","timolol%20maleate"],"PubChem":["104171325","11111904","11112709","11113334","144204165","170465062","90341807"],"Wikipedia":["Timolol"],"drugbank":["DB00373"],"chEBI":["9599"]},"childChemblIds":["CHEMBL1200870"],"count":11,"approvedIndications":["EFO_0004190","EFO_1001069","EFO_0000319","EFO_0000516"],"linkedTargets":{"rows":["ENSG00000169252","ENSG00000043591"],"count":2},"linkedDiseases":{"rows":["EFO_0004190","EFO_1001069","EFO_0004683","EFO_1000879","EFO_0000756","EFO_0003821","EFO_1000809","EFO_0000319","EFO_0000666","EFO_1001923","EFO_0000546","EFO_0003966","EFO_1001022","Orphanet_774","EFO_0000516","EFO_1000635","EFO_0004235"],"count":17},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 4 approved and 7 investigational indications."}
{"id":"CHEMBL507795","canonicalSmiles":"CC1=CCC(O)(C(C)C)CC1","inchiKey":"WRYLYDPHFGVWKC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TERPINEOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Terpineol"],"crossReferences":{"PubChem":["144212102"],"Wikipedia":["Terpinen-4-ol","Terpineol"],"drugbank":["DB12816"],"chEBI":["78884"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL523367","canonicalSmiles":"COc1cc(C(C#N)(CCCN(C)CCc2ccccc2)C(C)C)cc(OC)c1OC","inchiKey":"IERWCEALNGTKIK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METHOXYVERAPAMIL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(+/-)-Methoxyverapamil","D-600","DL-D-600","Gallopamil","LU-30-029","Methoxyverapamil"],"count":1,"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL537884","canonicalSmiles":"CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc21)OCOC(=O)C(C)(C)C.Cl","inchiKey":"LKBNSIRTOLAGCQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL537884","maximumClinicalTrialPhase":0,"parentId":"CHEMBL922","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL545315","canonicalSmiles":"C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1.Cl.Cl","inchiKey":"JZZFDCXSFTVOJY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CANERTINIB DIHYDROCHLORIDE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL31965","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CI-1033","Canertinib dihydrochloride","PD-0183805","PD-0183805-002B","PD-183805","SN-26606"],"count":3,"linkedTargets":{"rows":["ENSG00000146648","ENSG00000178568","ENSG00000141736"],"count":3},"linkedDiseases":{"rows":["EFO_0003869","MONDO_0021117","EFO_0003060"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL552212","canonicalSmiles":"CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1","inchiKey":"MTJHLONVHHPNSI-IBGZPJMESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEXIBULIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CYT 997","CYT-997","CYT997","Lexibulin"],"count":2,"linkedTargets":{"rows":["ENSG00000261456","ENSG00000167553","ENSG00000127824","ENSG00000188229","ENSG00000198033","ENSG00000258947","ENSG00000152086","ENSG00000196230","ENSG00000104833","ENSG00000167552","ENSG00000137267","ENSG00000101162","ENSG00000137285","ENSG00000123416","ENSG00000176014"],"count":15},"linkedDiseases":{"rows":["EFO_0001378","EFO_0000519"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL553426","canonicalSmiles":"CC[C@@H](N)C(=O)O","inchiKey":"QWCKQJZIFLGMSD-GSVOUGTGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"(R)-2-Aminobutanoic Acid","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(R)-2-Aminobutanoic Acid"],"crossReferences":{"drugbank":["DB04454"],"chEBI":["28797"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL557915","canonicalSmiles":"O=C(CN1CC[C@@H](NC(=O)c2ccc(Cl)s2)C1)Nc1ccc(-n2ccccc2=O)cc1F","inchiKey":"IYGIXVNAMZPBDK-CQSZACIVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL557915","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07872"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL573887","canonicalSmiles":"CNC(=O)[C@@H](NC(=O)[C@H](OCc1ccccc1)[C@H](O)[C@@H](O)[C@@H](OCc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O)C(C)C","inchiKey":"VZNNJZGVQVNHCM-CDNLURBZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL573887","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04255"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL574737","canonicalSmiles":"CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O","inchiKey":"PBCZSGKMGDDXIJ-KRUBCLEUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"UCN-01","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["KRX-0601","KW-2401","NSC-638850","UCN-01","UCN-02","Ucn 01","Ucn-01"],"count":43,"linkedTargets":{"rows":["ENSG00000154229","ENSG00000065675","ENSG00000123374","ENSG00000135446","ENSG00000171132","ENSG00000126583","ENSG00000105810","ENSG00000166501","ENSG00000163558","ENSG00000140992","ENSG00000115825","ENSG00000149554","ENSG00000067606","ENSG00000163932","ENSG00000027075","ENSG00000184304"],"count":16},"linkedDiseases":{"rows":["EFO_1000419","EFO_0002938","MONDO_0044964","EFO_0000756","MONDO_0007254","MONDO_0003196","EFO_0004252","EFO_0000209","MONDO_0002087","MONDO_0003541","EFO_0000565","MONDO_0001056","EFO_0004251","EFO_1000044","EFO_1001013","MONDO_0002158","EFO_0000339","EFO_0006352","MONDO_0002974","MONDO_0005411","EFO_0000673","EFO_0004193","EFO_0000198","EFO_0000616","EFO_0000221","MONDO_0001852","MONDO_0002537","EFO_0002618","MONDO_0021321","MONDO_0019457","MONDO_0008170","Orphanet_44890","EFO_1001512","MONDO_0004669","EFO_0000223","MONDO_0007576","EFO_0007535","EFO_0000224","MONDO_0008315","EFO_0003060","MONDO_0001879","EFO_0003025","Orphanet_398934","EFO_1000407","MONDO_0044787","EFO_0003028","EFO_0005537","EFO_0000702","EFO_0000574","MONDO_0002367","EFO_0000218","EFO_0003027","MONDO_0044926"],"count":53},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 43 investigational indications."}
{"id":"CHEMBL604","drugType":"Small molecule","blackBoxWarning":false,"name":"CUPRIC SULFATE","yearOfFirstApproval":1987,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Caustic Powder","Copper Sulfate","Cupric sulfate"],"synonyms":["Copper sulfate","Cupric Sulfate","Cupric sulfate","E519"],"crossReferences":{"DrugCentral":["4282"],"Wikipedia":["Copper(II)_sulfate"],"chEBI":["23414"]},"count":3,"approvedIndications":["EFO_0004272","EFO_0001070","HP_0001891"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 3 approved indications."}
{"id":"CHEMBL609880","canonicalSmiles":"C[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O","inchiKey":"SHZGCJCMOBCMKK-PHYPRBDBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"Alpha-D-Fucopyranose","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Alpha-D-Fucopyranose"],"crossReferences":{"drugbank":["DB03485"],"chEBI":["42564"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL650","canonicalSmiles":"C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12","inchiKey":"VHRSUDSXCMQTMA-PJHHCJLFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METHYLPREDNISOLONE","yearOfFirstApproval":1957,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Medrol","Medrone","Methylprednisolone"],"synonyms":["J3.872E","Methylprednisolone","NSC-19987","U-67,590A"],"crossReferences":{"DailyMed":["methylprednisolone"],"PubChem":["144203927","144212335","170465051","56424125","82706","855789"],"Wikipedia":["Methylprednisolone"],"drugbank":["DB00959"],"chEBI":["6888"]},"childChemblIds":["CHEMBL1200844"],"count":117,"approvedIndications":["EFO_0003106","EFO_0003885","EFO_0000729","MP_0001845","EFO_0000685","EFO_0002506","EFO_0000270","EFO_1001435","EFO_0003778","EFO_0000274","EFO_0003894","EFO_0000384","EFO_1000941"],"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["Orphanet_64739","EFO_0007486","MONDO_0100130","EFO_0000756","EFO_0004278","MONDO_0002959","EFO_1001345","EFO_0005952","HP_0011868","EFO_1001909","HP_0011950","EFO_0003914","HP_0100543","EFO_0003103","EFO_0002690","EFO_0003884","EFO_0004991","EFO_0000198","MONDO_0013730","EFO_0009012","HP_0012532","EFO_0001642","EFO_0007537","HP_0009926","EFO_0000662","EFO_0000384","MONDO_0008315","Orphanet_95","Orphanet_567","EFO_0000546","GO_0007568","EFO_1001365","EFO_0003032","EFO_1000391","EFO_0003957","MONDO_0016226","EFO_0000574","EFO_0004256","EFO_0001378","EFO_0000341","Orphanet_84","EFO_0003086","EFO_0007405","EFO_0007498","MONDO_0007254","EFO_0000255","EFO_1000637","HP_0004448","MONDO_0002135","HP_0002829","MONDO_0002158","EFO_1001254","Orphanet_77260","EFO_0000196","EFO_0004143","EFO_0007208","EFO_0004826","EFO_0000183","EFO_0000694","EFO_0000616","EFO_0000403","EFO_0003898","EFO_0003929","MONDO_0000870","EFO_0003843","EFO_0004599","EFO_0007149","EFO_0003885","EFO_0000684","EFO_0005297","Orphanet_238510","EFO_1001947","MONDO_0018906","EFO_0000557","EFO_0007167","EFO_0009492","EFO_0003956","EFO_0000729","Orphanet_309015","EFO_1000905","EFO_1001139","EFO_0003777","EFO_0003869","EFO_1000809","MONDO_0000956","EFO_0009373","EFO_1001919","MONDO_0100062","EFO_0000540","EFO_0000565","EFO_0000309","EFO_0007160","EFO_0007448","EFO_0004251","EFO_0002506","MONDO_0015540","EFO_0000253","EFO_0007332","EFO_0005761","EFO_0004145","EFO_0000220","EFO_0002508","MONDO_0008170","EFO_1001466","EFO_0003821","EFO_0004194","MONDO_0044881","EFO_1000784","HP_0001873","MP_0001845","EFO_0003840","MONDO_0100096","EFO_0000270","EFO_0002428","MONDO_0009348","EFO_0006862","Orphanet_282","EFO_1000965","MONDO_0015686","EFO_1001435","MONDO_0044887","EFO_0003778","EFO_0000274","EFO_0000209","HP_0001915","EFO_0007295","EFO_0004246","Orphanet_70589","EFO_0004254","EFO_1001801","Orphanet_309144","EFO_0007224","MONDO_0020743","HP_0002015","EFO_0010580","EFO_0000717","EFO_0000685","HP_0002140","EFO_0003894","EFO_1000941","EFO_0003060","EFO_0000311","EFO_0003106","EFO_0000211","EFO_0000095","EFO_0000706","EFO_0003766","MONDO_0020077"],"count":148},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 13 approved and 104 investigational indications."}
{"id":"CHEMBL65375","canonicalSmiles":"Cl.N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl","inchiKey":"KGHYQYACJRXCAT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TIPIRACIL HYDROCHLORIDE","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL235668","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["TAS-1-462","TPI","Tipiracil hydrochloride"],"crossReferences":{"DailyMed":["tipiracil%20hydrochloride"]},"count":3,"approvedIndications":["EFO_0000365"],"linkedTargets":{"rows":["ENSG00000025708"],"count":1},"linkedDiseases":{"rows":["EFO_1001480","EFO_0000365","EFO_1000657","MONDO_0044937"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for colorectal adenocarcinoma and has 2 investigational indications."}
{"id":"CHEMBL675","canonicalSmiles":"NCCCC(O)(P(=O)([O-])O)P(=O)(O)O.[Na+]","inchiKey":"CAKRAHQRJGUPIG-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"ALENDRONATE SODIUM","yearOfFirstApproval":1995,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL870","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alendronate sodium","Binosto","Fosamax"],"synonyms":["Alendronate sodium","Alendronate sodium hydrate","Alendronic acid monosodium salt trihydrate","G-704,650","G-704650","MK-217"],"crossReferences":{"DailyMed":["alendronate%20sodium"]},"count":5,"approvedIndications":["EFO_0004261","EFO_0003854","EFO_0003882"],"linkedTargets":{"rows":["ENSG00000160752"],"count":1},"linkedDiseases":{"rows":["EFO_0004261","EFO_0003854","MONDO_0007254","EFO_0003762","EFO_0003882"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 3 approved and 2 investigational indications."}
{"id":"CHEMBL696","canonicalSmiles":"CCC1(C)CC(=O)NC1=O","inchiKey":"HAPOVYFOVVWLRS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETHOSUXIMIDE","yearOfFirstApproval":1960,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Emeside","Ethosuximide","Suxinutin","Zarontin"],"synonyms":["CI-366","CN-10,395","CN-10395","Ethosuximide","NSC-64013","PM-671"],"crossReferences":{"DailyMed":["ethosuximide"],"PubChem":["144203921","170464802","174006922","26747515","26747516","50106318","50106319","85231037","90340672"],"Wikipedia":["Ethosuximide"],"drugbank":["DB00593"],"chEBI":["4887"]},"count":7,"approvedIndications":["EFO_0000474"],"linkedTargets":{"rows":["ENSG00000100346","ENSG00000006283","ENSG00000196557"],"count":3},"linkedDiseases":{"rows":["EFO_0005762","EFO_1001998","EFO_0000474","MONDO_0002050","EFO_0000555","EFO_0003821","HP_0001250","Orphanet_64280"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and is indicated for epilepsy and has 6 investigational indications."}
{"id":"CHEMBL70586","canonicalSmiles":"CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1","inchiKey":"NYKCGQQJNVPOLU-ONTIZHBOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SPIRADOLINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["U-62066"],"crossReferences":{"PubChem":["144206611","170466255"],"drugbank":["DB12704"]},"childChemblIds":["CHEMBL1256692"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL72434","canonicalSmiles":"CC(C)NC(=N)NO","inchiKey":"OITVEDMMUMUWTL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL72434","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02143"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL726","canonicalSmiles":"OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1","inchiKey":"PLDUPXSUYLZYBN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"FLUPHENAZINE","yearOfFirstApproval":1959,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Fluphenazine","NSC-62323","Permitil","Prolixin"],"crossReferences":{"DailyMed":["fluphenazine%20hydrochloride"],"PubChem":["104171155","11111179","11111180","144203697","170465375","26751625","50100242","50104297","57287813","90341540"],"TG-GATEs":["37"],"Wikipedia":["Fluphenazine"],"drugbank":["DB00623"],"chEBI":["5123"]},"childChemblIds":["CHEMBL1200792","CHEMBL1448187"],"count":2,"approvedIndications":["EFO_0005407"],"linkedTargets":{"rows":["ENSG00000149295"],"count":1},"linkedDiseases":{"rows":["EFO_0005407","EFO_0001378","EFO_0000692"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for psychosis and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL754","canonicalSmiles":"O=C([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+]","inchiKey":"DFHAXXVZCFXGOQ-UHFFFAOYSA-K","drugType":"Small molecule","blackBoxWarning":true,"name":"FOSCARNET SODIUM","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL666","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Foscarnet sodium","Foscavir"],"synonyms":["A-29622","EHB 776","EHB-776","Foscarnet sodium","Foscarnet sodium hexahydrate","Foscarnet sodium hydrate","Foscavir"],"crossReferences":{"DailyMed":["foscarnet%20sodium"],"PubChem":["144204917","170465060","26748573"],"chEBI":["141644"]},"count":4,"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL77562","canonicalSmiles":"O=C(O)c1cc(C(=O)O)cc(C(=O)O)c1","inchiKey":"QMKYBPDZANOJGF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"1,3,5-Benzenetricarboxylic Acid","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["1,3,5-Benzenetricarboxylic Acid","Benzene-1,3,5-Tricarboxylic Acid"],"crossReferences":{"PubChem":["144207215"],"Wikipedia":["Trimesic_acid"],"drugbank":["DB08632"],"chEBI":["46032"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL806","canonicalSmiles":"CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1","inchiKey":"MKXKFYHWDHIYRV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"FLUTAMIDE","yearOfFirstApproval":1989,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Chimax","Drogenil","Eulexin","Flutamide"],"synonyms":["Flutamide","NSC-215876","SCH 13521","SCH-13521"],"crossReferences":{"DailyMed":["flutamide"],"PubChem":["104171162","11111202","11111203","11532925","124880151","124880153","144203705","144209367","144210854","170464921","17388997","174007322","26747365","26747366","26753014","26753015","49675006","50105597","50105598","50105599","50105600","85231055","90341271"],"TG-GATEs":["44"],"Wikipedia":["Flutamide"],"drugbank":["DB00499"],"chEBI":["5132"]},"count":7,"approvedIndications":["EFO_0000616","EFO_0000673","EFO_0001663"],"linkedTargets":{"rows":["ENSG00000169083"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","MONDO_0008170","EFO_0000673","MONDO_0008315","EFO_0000660","EFO_0001663","Orphanet_418"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL814","canonicalSmiles":"COCCCC/C(=N\\OCCN)c1ccc(C(F)(F)F)cc1","inchiKey":"CJOFXWAVKWHTFT-XSFVSMFZSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"FLUVOXAMINE","yearOfFirstApproval":1994,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Fluvoxamine","N06AB08"],"crossReferences":{"DailyMed":["fluvoxamine%20maleate"],"PubChem":["104171369","144204388","170464809","26751469","50103976","90340960"],"Wikipedia":["Fluvoxamine"],"drugbank":["DB00176"],"chEBI":["5138"]},"childChemblIds":["CHEMBL1409"],"count":11,"approvedIndications":["EFO_0003761","EFO_1002014"],"linkedTargets":{"rows":["ENSG00000108576"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0004262","MONDO_0002009","HP_0000726","EFO_0003758","EFO_1002014","EFO_1001917","EFO_1001916","EFO_1001892","MONDO_0002050","MONDO_0100096","EFO_0003761","EFO_0004242","EFO_0005230","EFO_0000692"],"count":15},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for unipolar depression and melancholia and has 9 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL819","canonicalSmiles":"Cc1onc(-c2ccccc2)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12","inchiKey":"UWYHMGVUTGAWSP-JKIFEVAISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXACILLIN","yearOfFirstApproval":1971,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Oxacillin","Prostaphlin"],"crossReferences":{"Wikipedia":["Oxacillin"],"drugbank":["DB00713"],"chEBI":["7809"]},"childChemblIds":["CHEMBL693","CHEMBL3989567"],"count":5,"approvedIndications":["EFO_0000771"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and is indicated for bacterial disease and has 4 investigational indications."}
{"id":"CHEMBL842","canonicalSmiles":"NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O","inchiKey":"JBMKAUGHUNFTOL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHLOROTHIAZIDE","yearOfFirstApproval":1958,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Chlorothiazide","Diuril","Saluric"],"synonyms":["Chlorothiazide","Chlorthiazide","Hydrochlorothiazide impurity, chlorothiazide-","NSC-25693"],"crossReferences":{"DailyMed":["chlorothiazide","chlorothiazide%20sodium"],"PubChem":["11110950","11110951","144203658","144208170","170465303","17389544","50105505","855976"],"Wikipedia":["Chlorothiazide"],"drugbank":["DB00880"],"chEBI":["3640"]},"childChemblIds":["CHEMBL1200616"],"count":8,"approvedIndications":["EFO_0004255","EFO_0000373","EFO_0000319","EFO_0000537"],"linkedTargets":{"rows":["ENSG00000070915"],"count":1},"linkedDiseases":{"rows":["EFO_0003914","HP_0012664","EFO_0003777","HP_0003124","EFO_0003144","EFO_0001645","EFO_0004255","EFO_0000373","EFO_0000319","EFO_0001360","EFO_0000537"],"count":11},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1958 and has 4 approved and 4 investigational indications."}
{"id":"CHEMBL87992","canonicalSmiles":"CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc21","inchiKey":"QIALRBLEEWJACW-INIZCTEOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ESLICARBAZEPINE ACETATE","yearOfFirstApproval":2009,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aptiom","Erelib","Pazzul","Stedesa","Zebinix"],"synonyms":["BIA 2-093","BIA-2-093","BIA-2093","Eslicarbazepine acetate","SEP - 0002093","SEP-0002093"],"crossReferences":{"DailyMed":["eslicarbazepine%20acetate"],"PubChem":["29217508","90341297"],"drugbank":["DB09119"],"chEBI":["87016"]},"count":8,"approvedIndications":["EFO_0000474","HP_0001250"],"linkedTargets":{"rows":["ENSG00000185313","ENSG00000196876","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169432","ENSG00000168356","ENSG00000136531","ENSG00000007314","ENSG00000153253"],"count":10},"linkedDiseases":{"rows":["EFO_0005762","EFO_1000783","EFO_1000877","EFO_0000474","EFO_0005687","EFO_0004263","EFO_0003821","EFO_0009963","EFO_0006510","HP_0001250"],"count":10},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for seizure and epilepsy and has 6 investigational indications."}
{"id":"CHEMBL90568","canonicalSmiles":"COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1O","inchiKey":"MBNGWHIJMBWFHU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIOSMETIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Diosmetin","Diosmetine"],"crossReferences":{"PubChem":["174007266","26756923"],"Wikipedia":["Diosmetin"],"drugbank":["DB11259"],"chEBI":["4630"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL91","canonicalSmiles":"Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1","inchiKey":"BYBLEWFAAKGYCD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MICONAZOLE","yearOfFirstApproval":1974,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Conofite","Dermazole","Dumicoat","Loramyc","Micatin","Monistat","Monistat-3","Monistat-Derm","Oravig"],"synonyms":["Miconazole","Monistat-Derm","NSC-170986","Vusion"],"crossReferences":{"DailyMed":["miconazole","miconazole%20nitrate"],"PubChem":["144204152","443253","85148356"],"Wikipedia":["Miconazole"],"drugbank":["DB01110"],"chEBI":["82892"]},"childChemblIds":["CHEMBL1559","CHEMBL4578119"],"count":3,"approvedIndications":["EFO_0000544"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for infection and has 2 investigational indications."}
{"id":"CHEMBL924","canonicalSmiles":"O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O","inchiKey":"XRASPMIURGNCCH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZOLEDRONIC ACID","yearOfFirstApproval":2001,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aclasta","Reclast","Zerlinda","Zoledronic acid","Zometa"],"synonyms":["AK-156","CGP 42446","CGP-42446","CGP-42446A","Zoledronic acid","Zoledronic acid hydrate","Zoledronic acid monohydrate","Zometa"],"crossReferences":{"DailyMed":["zoledronic%20acid"],"PubChem":["144205292","174006914","29215499"],"Wikipedia":["Zoledronic_acid"],"drugbank":["DB00399"],"chEBI":["46557"]},"childChemblIds":["CHEMBL3989655","CHEMBL4303669","CHEMBL2103912"],"count":53,"approvedIndications":["EFO_0004261","EFO_0003854","EFO_0000196","EFO_0000673","EFO_0001378","EFO_0004260","EFO_0003882","EFO_0001663","EFO_0009708"],"linkedTargets":{"rows":["ENSG00000160752"],"count":1},"linkedDiseases":{"rows":["EFO_0003869","EFO_0000637","EFO_0000681","EFO_1001919","Orphanet_848","EFO_0005952","EFO_1001147","EFO_0000228","EFO_1001152","EFO_0000333","HP_0000938","EFO_0003931","EFO_0000339","EFO_0000588","MONDO_0002974","EFO_1000786","MONDO_0020732","EFO_0000182","MONDO_0008903","HP_0003419","EFO_0009870","EFO_0001416","Orphanet_740","EFO_0004260","MONDO_0008315","EFO_0001663","EFO_0009708","EFO_0000432","EFO_0001378","EFO_0003922","EFO_1001998","MONDO_0044903","EFO_0003820","EFO_0001365","Orphanet_232","MONDO_0007254","Orphanet_586","EFO_0004252","EFO_0003882","EFO_0002430","EFO_1000044","EFO_1001996","EFO_0000673","EFO_0000196","EFO_0000685","EFO_0004261","Orphanet_666","EFO_0003843","EFO_0003060","EFO_0000621","EFO_0006738","MONDO_0002171","EFO_0003863","EFO_0003854","EFO_0000649","EFO_0000764","EFO_0000174","MONDO_0002367","MONDO_0024880","EFO_0000691","EFO_0004259"],"count":61},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 9 approved and 44 investigational indications."}
{"id":"CHEMBL9352","canonicalSmiles":"O=C1C[C@@H](c2ccc(O)cc2)Oc2cc(O)cc(O)c21","inchiKey":"FTVWIRXFELQLPI-ZDUSSCGKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NARINGENIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-11855"],"crossReferences":{"PubChem":["11112355","11113265","22405473"],"Wikipedia":["Naringenin"],"drugbank":["DB03467"],"chEBI":["17846"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL936","canonicalSmiles":"OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1","inchiKey":"OGAKLTJNUQRZJU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIPHENIDOL","yearOfFirstApproval":1967,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Vontrol"],"synonyms":["Difenidol","Difenidol hydrochloride","Diphenidol","SK&F 478","SK&F-478","SK-478","Vontrol"],"crossReferences":{"PubChem":["11112531","144206624","170465280","50100475"],"Wikipedia":["Diphenidol"],"drugbank":["DB01231"],"chEBI":["4638"]},"childChemblIds":["CHEMBL2105784","CHEMBL1529"],"linkedTargets":{"rows":["ENSG00000168539"],"count":1},"linkedDiseases":{"rows":["EFO_0006862","HP_0002321"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1967."}
{"id":"CHEMBL972","canonicalSmiles":"C#CCN(C)[C@H](C)Cc1ccccc1","inchiKey":"MEZLKOACVSPNER-GFCCVEGCSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"SELEGILINE","yearOfFirstApproval":1989,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Eldepryl","Emsam","Zelapar"],"synonyms":["Eldepryl","Selegiline","Zelapar"],"crossReferences":{"DailyMed":["selegiline","selegiline%20hydrochloride"],"PubChem":["11113910","26752066"],"Wikipedia":["Selegiline"],"drugbank":["DB01037"],"chEBI":["9086"]},"childChemblIds":["CHEMBL1200904"],"count":6,"approvedIndications":["EFO_0002508","EFO_0003761"],"linkedTargets":{"rows":["ENSG00000069535"],"count":1},"linkedDiseases":{"rows":["EFO_0007191","EFO_0002610","MONDO_0002050","EFO_0000289","MONDO_0002009","HP_0012076","EFO_0002508","EFO_0000249","EFO_0000673","EFO_0003761","EFO_0003768","EFO_0004701","EFO_0000692"],"count":13},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and is indicated for parkinson's disease and unipolar depression and has 4 investigational indications. This drug has a black box warning from the FDA."}
